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Over the past decade, new and improved formulations of highly active antiretroviral 
therapy (HAART) have been introduced, which are easier to administer and may not 
necessitate high levels of adherence for HIV RNA suppression. At the same time, there 
has been an increase in the use of concomitant medications to treat chronic non-AIDS 
conditions (i.e., diabetes, hypertension) in HIV-infected persons. The goals of the 
dissertation were 1). to estimate the minimum cutoff of adherence to newer HAART 
needed for population HIV RNA suppression, 2). to determine whether this cutoff differed 
by specific regimen type, and 3). to determine if the increase in pill burden due to 
concomitant medication use impacted adherence to HAART.  
Methods 
We used data from three longitudinal cohort studies: the Multicenter AIDS Cohort Study 
(MACS), the AIDS Linked to Intravenous Experience (ALIVE), and the Veterans Aging 
Cohort Study Virtual Cohort (VACS) between 2001 and 2011, and analyzed them 
separately for this dissertation. Adherence was calculated from self-reported use in the 
MACS and ALIVE, and using pharmacy refill records in the VACS. In all three cohorts, 
the minimum needed adherence cutoff was defined as the level at which the odds of 
suppression was not significantly different than that observed with ≥95% adherence using 
repeated measures logistic regression. We controlled for confounding by indication using 
propensity score weighting. The effect of the number of concomitant medications on the 
minimum optimal adherence cutoff to HAART was also analyzed longitudinally using 
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repeated measures logistic regression models, and we further determined if this 
association varied by the pharmacologic class of the concomitant medication. 
Results 
In all three cohorts, there was an increase in the proportion with ≥95% adherence, and the 
proportion suppressed over time. Study 1 consisted of 1,006 HAART users with 10,971 
person-visits in the MACS, and 197 HAART users with 1,745 person-visits in the ALIVE. 
In the MACS, levels of adherence between 80-84% were sufficient for HIV RNA 
suppression (OR (ref ≥95%): 1.43(0.61, 3.33)). In the ALIVE, we did not observe a 
minimum adherence cutoff below 95%. Study 2 consisted of 21,865 HAART users who 
contributed 82,217 person-years of follow-up. Suppression with <95% adherence was less 
likely (p<0.05) for PI-based regimens, whereas NNRTI users suppressed virus with lower 
adherence levels, odds ratios: 1.1 (0.89,1.36) and 0.82 (0.64,1.04) for 90-94% and 85-89% 
adherence, respectively. Study 3 consisted of 1,194 MACS participants contributing 
11,678 person-years between 2001 and 2011, and 21,708 VACS patients contributing 
79,972 person-years between 2001 and 2010. The use of concomitant medication 
increased over time in both cohorts, and the odds of achieving the minimum optimal 
adherence increased with an increase in the number of concomitant medications. 
Conclusions 
Despite the lower adherence level needed for suppression, HIV-infected persons should be 
instructed to achieve near-perfect levels of adherence.  Providers should however not be 
reluctant to initiate HAART early in the infection, even to persons with historical barriers 
to adherence. Comprehensive counseling sessions and medication therapy management 
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Overview and Specific Aims 
Treatment complexity and side-effects are common barriers to adherence to 
HAART.  New formulations of HAART are simpler and also have improved 
pharmacokinetic profiles, i.e., longer half-lives, and reduce the need for complete 
adherence. Owing to a decrease in AIDS-related mortality and improved life expectancy 
over the past decade, there has been an increase in non-AIDS-related morbidity and 
mortality, and consequently the use of concomitant medications for non-AIDS 
comorbidities.   
This dissertation aims to evaluate the minimum level of adherence needed for 
HIV RNA suppression in the current HAART era, and determine if this minimum level 
of adherence is impacted by the increased use of concomitant medications for chronic 
non-AIDS comorbidities. Specifically, 
Aim 1: To estimate the minimum optimal adherence level to HAART to achieve HIV 
RNA viral load suppression from 2001 through 2011. 
 Hypothesis 1a:  Adherence to HAART has improved over time. 
Hypothesis 1b: The minimum adherence level to achieve HIV RNA suppression 
has decreased over time. 
Aim 2: To estimate the minimum optimal adherence level to HAART to achieve HIV 
RNA viral load suppression by HAART regimen type from 2001 through 2010. 
Hypothesis 2a: The minimum adherence level to achieve HIV RNA suppression is 
different by HAART regimen type  
3 
 
Aim 3: To determine the association between HAART adherence and the number of 
concomitant medications used for chronic non-AIDS comorbidities among current 
HAART users on concomitant medications from 2006 to 2011. 
Hypothesis 3a: The adherence to HAART decreases with an increase in the 






















Treatment of HIV Infection 
Highly active antiretroviral therapy (HAART) was first introduced in 1996, and 
consisted then of a highly complex combination of antiretrovirals (ARV) which was 
difficult to administer owing to frequent dosing schedules and poor toxicity profiles.
1,2
 
Over the past decade, ARV formulations have become easy to administer, and have 
enhanced potency and toxicity profiles compared to their predecessors.
3,4,5
 Based on the 
changing landscape of HAART, the treatment of HIV can be classified into 3 treatment 
eras (Figure 1.1): the early HAART era (1996-2000), when treatment consisted of 
nucleoside/nucleotide reverse transcriptase inhibitors (NRTI) or protease inhibitors (PI)-
based regimens; the mid HAART era (2001-2005) when boosted PIs and newer classes 
like entry/fusion inhibitors were introduced, and the use of nonnucleoside reverse 
transcriptase inhibitor (NNRTI)- based regimens started gaining ground; the current 
HAART era (2006 onward), when the first single fixed dose-combination drug Efavirenz 
(EFV)/Tenofovir (TDF)/Emtricitabine (FTC) was approved, second generation NNRTIs 
like Etravirine (ETV) were approved for use, and a new drug class Integrase Strand 
Transfer Inhibitors (INSTI)-based regimens was introduced.
6
   
Currently, there are over 6 pharmacological classes and 30 ARVs approved by the 
FDA (Table 1.1). 
6
 According to current Department of Health and Human Services 
(DHHS) guidelines, “the optimal initial ARV regimen for a treatment-naive patient 
consists of two NRTIs in combination with a drug from one of three drug classes: an 
NNRTI, a PI boosted with ritonavir (RTV), or an INSTI.”
6
  Initial HAART regimens are 





to resistance, individual intolerance to medications, and potential drug-drug interactions, 
regimen changes are required. Among ART-naïve individuals, the median time to 
switching regimens is 8 months, and a recent study showed that 41% of HIV-infected 




Adherence to HAART 
An integral component of the successful management of HIV, similar to that of 
other chronic illnesses, is a high level of adherence to treatment.  Adherence to treatment 
is defined as “the extent to which patients take their medications as prescribed, starts with 
initiation of therapy, which occurs when the patient takes the first dose, and continues 
with the implementation of the dosing regimen, represented by the extent to which a 
patient’s actual dosing corresponds to the prescribed dosing regimen.”
6,8
 There is 
currently no gold standard measure for adherence in large population-based studies, but 
there are several validated tools available to use in different settings.
3,8,9
 Adherence to 
HAART may be measured using direct methods such as measuring the drug levels in the 
blood, and indirect methods such as self-report, pill counts, pharmacy refills, and 
electronic monitoring devices. Table 1.2 shows the different methods used for assessing 
adherence to medication regimens, and their advantages and disadvantages for use.  
 In order to achieve and sustain viral load suppression, an adherence threshold of 
95% was established as necessary.
10,11
 Maintaining high levels of adherence over a long 
period of time is impaired due to numerous patient-, treatment- and disease-related 
factors. Virologic and immunologic outcomes, durability of responses, tolerability, drug-





associated with HAART adherence include side-effects, regimen complexity,
13,14 
 
frequency of dosing, size of the pill, dietary considerations, and treatment cost.
15,16,17
 
Behavioral factors such as high-risk behaviors (i.e., use of non-prescription drugs), 
depression and other mental illnesses,
18,19,20
 sociodemographic factors such as age, race, 
gender, and education,
21
 and structural factors such as lack of social support, stigma, 
homelessness, poor access to treatment, incarceration, and lack of adherence counseling 
at the clinical setting also impact optimal adherence to HAART.
 22,23,24,25
 
As a consequence of needing to maintain a high optimal adherence threshold, 
providers may be discouraged from prescribing HAART universally to patients early in 
the infection due to potential barriers to sustaining high levels of adherence over time, in 
addition to potential acute and chronic complications of HAART.
26
  Historically, 
HAART was initiated when the disease was symptomatic or at low levels of CD4 cell 
count.
27
 Current guidelines recommend the use of HAART in all HIV-infected persons, 
irrespective of their CD4 cell count in order to prevent progression of the disease, and 
transmission of the infection to HIV-negative persons at risk.
6
 They also state:  
“Regardless of CD4 count, the decision to initiate ART should always include 
consideration of a patient’s comorbid conditions, his or her willingness and 
readiness to initiate therapy, and available resources. In settings where there are 
insufficient resources to initiate ART in all patients, treatment should be 
prioritized for patients with the following clinical conditions: pregnancy; CD4 
count <200 cells/mm
3
 or history of an AIDS-defining illness including HIV-
associated dementia, HIV-associated nephropathy (HIVAN), or hepatitis B virus 
(HBV); and acute HIV infection.”
6
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Providers therefore make the decision to initiate treatment based on other patient-related 
factors that may impact adherence to HAART. 
For patients on HAART, maintaining long-term adherence requires significant 
time and resources.
28,29
 This involves a multi-pronged approach starting with 
strengthening of the patient-provider relationship, ensuring linkage and retention in care, 
involving a multidisciplinary team (i.e., clinicians, pharmacists, nurses).  An important 
component is educating the patient about HIV infection, HAART, and consequences of 
not adhering to treatment.  Adherence monitoring, which typically involves patient 
interviews, patient diaries, as well as measurement of viral load, will not only enable the 
provider to learn how adherent the patient is, but also identify reasons for poor 
adherence.
30,31
 Targeting specific barriers to adherence is the next step, which ranges 
from pill box organizers, and electronic reminders, to providing prescription drug 
coverage, and resource-intensive interventions to improve adherence.
32,33
 Treatment 
adherence interventions include motivational interviews, community resources, 
administration of medications under supervised settings (e.g., Directly Administered 
Antiretroviral Therapy (DAART)
 
for drug users), self-monitoring, regular counseling, 
incentives to improve clinic retention, and other adherence improvement strategies such 
as Sharing Medical Adherence Responsibilities Together (SMART for couples).
32,33,34
 
Although these interventions have been proven to be effective in improving adherence, 
they may not be beneficial in the long-term unless base-level infrastructural factors such 
as social support, income, insurance status, and homelessness are targeted. Providing the 
most optimal ARV regimen given individual barriers to treatment will be also cost-
effective in the long run. 
8 
 
Minimum optimal adherence in the current era of treatment 
 In the current era of HIV treatment, with ease of administration of HAART, 
studies have shown that the use of once-daily HAART may enhance the overall 
adherence to treatment compared with twice-daily dosing.
13,35,36,37,38 
Concomitantly, the 
improved pharmacokinetic profiles of second-generation formulations like boosted PI-
based regimens (i.e., ritonavir-boosted atazanavir (ATV/r)), NNRTI-based regimens (i.e., 
rilpivirine (RPV) and etravirine (ETV)), and newer classes (i.e., INSTI-based regimens: 
raltegravir (RTG), elvitegravir (ETG)) have allowed for missing doses, and favorable 
treatment outcomes at moderate levels of adherence.
39
 Table 1.1 shows the recommended 
HAART regimens in the current DHHS guidelines.  
Although the recommended regimens have comparable efficacy, several factors 
that are taken into account in prescribing the most optimal regimen include safety 
considerations (i.e., adverse drug reactions, drug-drug interactions with concomitant 
medications), ease of administration (i.e., dosing frequency, number of pills, dietary 
requirements), the resistance profile, and the presence of comorbidities. Safety 
considerations vary for individual ARVs, and other concomitant medications which are 
administered. While NNRTI-based regimens are convenient to administer, boosted PI-
based regimens have relatively low half-lives, and require frequent dosing.
6
 The use of 
boosted PI-based regimens has however been suggested in persons with poor adherence 
owing to their improved potency and tolerability, and relatively high barrier for 
resistance.
6
 In order to decrease the pharmacological activity of this class, several viral 









Given the intrinsic characteristics of specific HAART regimens, there is differing 
evidence regarding the levels of adherence needed for different HAART regimens. 
Maggiolo et al and Bangsberg
40
 reported that moderate levels of adherence led to higher 
rates of viral suppression in NNRTI-treated patients compared with individuals receiving 
a single PI- or a boosted PI-based regimen.  A later study by Chesney et al reported viral 
suppression for NNRTI-based regimens at adherence levels down to 55% to 75%.
14,41
  
However, a recent study by Genberg et al showed that non-adherence to NNRTI-based 
regimens was associated with worse outcomes compared to boosted PI-based regimens.
42
  
While studies have shown that levels of adherence lower than 95% may be 
sufficient for viral load suppression, the minimum level of adherence needed for 
virologic suppression has not been established. Aim 1 attempts to fill this gap by 
determining a minimum optimal cutoff in the current era of treatment in two distinct risk 
groups. Further, since the adherence levels may vary by HAART regimen type, it is 
important to determine the levels of adherence specific to individual HAART regimens. 
Aim 2 determines whether the minimum optimal level of adherence is different by 
HAART regimen type. 
 
Significance of a lower minimum optimal adherence cutoff 
A report by the Institute of Medicine has stated that “increased focus on why 
people diagnosed with HIV fail to enter or remain in HIV care, as well as removing 
obstacles to care, such as by providing supportive services, will improve individual health 
10 
 
and reduce transmission of HIV to others.”
43
 A lower minimum optimal adherence cutoff 
to treatment will encourage providers to initiate treatment early in the infection, and also 
enable providers to focus attention on poor adherers and persons with barriers to 
treatment.  The use of the most optimal regimen in persons with barriers to treatment 
adherence will help prevent drug resistance and virologic failure.   
 
Aging, comorbidities, polypharmacy 
The simplification and improved effectiveness of HAART has been accompanied 
by a decrease in AIDS-related morbidity and mortality, and longevity of HIV-infected 
persons.
44,45
 Aging in HIV-infected persons is also accelerated as a result of inflammation 
and HAART-related side-effects.
46
  As a consequence, polypharmacy is now increasingly 
prevalent in HIV-infected populations.  
Polypharmacy, defined as the use of over 5 medications from different regimens, 
has led to treatment complexity in HIV-infected persons.
47
 Some commonly used 
concomitant medications for non-AIDS conditions include antilipidemics, 
antihypertensives, oral hypoglycemics and antidepressants.
48,49
 Polypharmacy has led to 
an increase in the total pill burden in HIV-infected patients.
50
 There is strong evidence on 
the negative impact of pill burden on adherence to HAART.
13,14
  However, there is 
limited data on whether the number of concomitant medications used for non-AIDS 
comorbidities impacts adherence to HAART.  Moreover, this may likely vary depending 
on the use of particular HAART regimens, since the choice of the concomitant 
medication is often influenced by the HAART regimen type.
48
 For instance, INSTI-based 
regimens are preferred over other regimens for coadministration with antidepressants 
11 
 
owing to potential drug-drug interactions between antidepressants and NNRTI-and PI-
based regimens.  
Age is a strong predictor of concomitant medication use, whereby older persons 
use more concomitant medications than younger persons.
49
 Older persons are also better 
retained in care and adherent to their medications.
51
 However, increase in the treatment 
complexity involves regular monitoring of potential drug-drug interactions and adverse 
events.
49,51
 The presence of comorbidities like metabolic disorders and chronic kidney 
disease and the pathophysiology of aging itself may also impact overall drug 
pharmacodynamics, and reduce the efficacy of HAART.
52
   
Therefore, the long-term use of concomitant medications for non-AIDS 
conditions is complicated, and may obscure the benefits of improved HAART 
formulations.
50
 Identifying modifiable risk factors of adherence to HAART and 
concomitant medication use will provide targets for intervention. It will also help 
providers learn about factors impacting treatment management in the current HAART 
era. Aim 3 seeks to address this issue of increased treatment complexity as a result of 
concomitant medication use for chronic non-AIDS comorbidities, and its impact on 
adherence to HAART.  
 
Conceptual framework and study variables 
 Figure 1.2 shows the conceptual framework for these investigations.  Several 
factors at the individual level serve as predictors for adherence to HAART and HIV RNA 
suppression, including sociodemographic factors (i.e., age, race, sex, income, education, 
insurance status, marital status), behavioral factors (i.e., substance use, perception of 
12 
 
disease), structural factors (i.e., social support, access to care, incarceration, 
homelessness), comorbidities, concomitant medication use, and HIV disease indices, 
including virologic and immunologic outcomes. Achieving and maintaining high levels 
of adherence leads to viral load suppression. The minimum level of adherence needed to 
achieve viral load suppression is defined as the minimum optimal adherence. The type of 
HAART regimen prescribed is impacted by individual-level factors and treatment 
outcomes, and is a predictor of adherence to HAART and HIV RNA suppression. The 
number of concomitant medications used for chronic non-AIDS comorbidities is 
hypothesized to impact adherence to HAART, with more concomitant medication use 
leading to a decrease in adherence to HAART.   
 
Study population and data sources 
This dissertation uses data from three prospective cohort studies of HIV-infected 
persons in the United States. Table 1.3 provides a description of the different populations 
used for this dissertation. Aim 1 uses data from the Multicenter AIDS Cohort Study 
(MACS)
53
 and the AIDS Linked to the Intravenous Experience (ALIVE)
54
 study, which 
are both interval cohorts consisting of HIV- infected men-who-have-sex-with-men 
(MSM) and injection drug users (IDU) populations, respectively. Data are collected every 
six months using standardized questionnaires, blood collection and physical 
examinations. Self-reported clinical outcomes are confirmed by review of medical 
records. The MACS enrolled participants at four study sites across the country in 
Baltimore MD, Pittsburgh PA, Los Angeles CA, and Chicago IL. The ALIVE consists of 
one study site in Baltimore MD.   
13 
 
Aim 2 uses data from the Veterans Aging Cohort Study virtual cohort (VACS 
VC).
55
 This cohort consists of administrative records, clinical data and pharmacy 
fill/refill records of HIV-infected persons presenting at a Veterans Health Administrative 
(VHA) site in the US. They were identified using electronic medical records based on a 
modified algorithm by Fasciano et al
56
 to identify HIV-infected persons based on a 
combination of one inpatient and two outpatient ICD-9 diagnosis codes.  
Aim 3 uses data from the MACS and the VACS VC cohorts. 
  
Overview of this dissertation 
This dissertation is organized into three publishable manuscripts representing Chapters 2, 
3, and 4. Chapter 2 aims to examine trends in adherence to HAART and viral load 
suppression between 2001 and 2011, and determine the minimum optimal adherence to 
HAART in the current era of treatment in HIV-infected MSM and IDU older than 18 
years in the US between 2006 and 2011 using data from the MACS and the ALIVE 
study. 
Chapter 3 aims to examine trends in adherence to HAART and viral load suppression 
between 2001 and 2010, and determine the minimum optimal adherence to HAART in 
the current era of treatment for specific HAART regimen types in HIV-infected veterans 
older than 18 years in the US between 2006 and 2010 in the VACS VC. 
Chapter 4 aims to determine the association between the number of concomitant 
medications used for chronic non-AIDS comorbidities in HIV-infected persons in the US 
older than 18 years, and using HAART since 2001 in the MACS and the VACS VC 
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Table 1.1 FDA Approved HAART classes
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Second generation drugs: 









- The single pill regimens are 
easy to administer 
- They have good virologic 
potency and durability 
- They have a low genetic 
barrier for the development of 
resistance especially in 
HAART-naïve patients 
 
Protease Inhibitors (PI) Unboosted: 
amprenavir (AMP), 
indinavir (IND), lopinavir 















ATV/r plus TDF/FTC 
DRV/r plus TDF/FTC 
ATV/r plus ABC/3TC 
LPV/r plus TDF/FTC 




- They have good virologic 
potency and durability in 
treatment-naïve patients 
- They have the potential for 
significant drug-drug-
interactions when 
administered with other 
concomitant medications 
owing to the inhibition of the 
cytochrome P (CYP) 450 
enzyme 
- PIs are also associated with 
metabolic abnormalities 
 





RAL plus TDF/FTC 
DTG plus ABC/3TC 
DTG plus TDF/FTC 
 









naïve patients as they have 
few drug-drug interactions 
since it does not inhibit the 
CYP450 pathway  
- They require more frequent 






















Table 1.2 Adherence measures
3,9
  
Type Adherence measure Advantages Disadvantages 
Direct measures Pharmacological and 
biochemical markers 
They have higher reliability and 
validity compared to indirect measures.  
It can be labor-intensive and 
costly to administer in the long 
run. 




They are cheap to administer, easy to 
collect, and used frequently in different 
settings. 
They may be associated with 
recall error. 
 Pharmacy refills Adherence can be monitored over a 
long period of time and it is especially 
useful to study adherence for chronic 
medications. 
They are used frequently in different 
settings.  
- They may misrepresent 
adherence as the medications 
may not be taken as prescribed. 
- They are not useful to monitor 
adherence over shorter periods.  
 Pill count They are feasible to use in day-to-day 
settings or clinical trials. 
They are time-consuming and 
may misrepresent adherence as 
they do not measure if the patient 
took the medication as prescribed. 
 MEMS cap They provide a good representation of 
adherence and patient medication use 
patterns that may not be possible using 
other measures.  
They are expensive and prone to 
malfunction and tampering. 
 Electronic medical 
records 
They can be used to monitor adherence 
over a period of time.  






Table 1.3  Summary of study populations for dissertation 
Design synopsis  Aim 1 Aim 2 Aim 3 
Study population HIV-infected persons in the 
MACS (N=1,006) and ALIVE 
(N=197)  
HIV-positive persons in VACS VC 
(N=21,865) 
HIV-infected persons in the 
MACS (N=1,194) and VACS 
VC (N=21,708) 
Eligibility criteria 1. older than 18 years 
2. on HAART between 2001 and 
2011 
1. older than 18 years 
2. on HAART between 2001 and 
2010 
1. older than 18 years 
2. on HAART between 
2001 and 2011 
 




























sociodemographic and behavioral 
characteristics: age, race, annual 
income, insurance status, current 
injection drug use, non-injection 
drug use, current smoking, and 
moderate-heavy alcohol intake; 
treatment and disease 
characteristics: number of ARVs, 
CD4 cell count, and self-reported 
depressive symptoms (CESD>16) 
 
 
Adherence to HAART (using 











sociodemographic and behavioral 
characteristics: age, race, 
geographical location, alcohol 
abuse, drug abuse, smoking; 
treatment and disease 
characteristics: HAART regimen 
type for a given patient in a year, 




Number of concomitant 
medications used for a 
chronic non-AIDS condition 
since the previous visit in the 
MACS or in a given year in 
the VACS 
 
Adherence to HAART (self-
reported in the MACS and 
using pharmacy refill records 




age, race, geographical 
location, alcohol use, 
recreational drug use, 
smoking; treatment and 
disease characteristics: 
HAART regimen type for a 
given patient in a year, 
depression, CD4 cell count, 
HIV RNA Suppression, 
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Design synopsis  Aim 1 Aim 2 Aim 3 
VACS Risk Index, presence 















































    NRTI combination therapy          HAART with PI             HAART no PI 
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Figure 1.2 Conceptual framework 
 
 
                                             
 

















sociodemographic factors: age, race, sex, 
income, insurance status, education, marital 
status 
behavioral factors: substance use, perception 
of disease  
structural factors: homelessness, social 
support, access to care, incarceration 
comorbidities 
concomitant medication use: type of 
concomitant medication  





Drug resistance HAART 
characteristics: 
regimen type, 
number of antiretrovirals, 
dosing frequency, pill size, 
safety, dietary considerations, 












CHAPTER  TWO 
Level of adherence and HIV RNA suppression in the current era of Highly Active 









Adherence to highly active antiretroviral therapy (HAART) has been a barrier for 
universal administration at early stages of HIV, with ≥95% adherence deemed necessary 
for treatment effectiveness.  Using longitudinal data from the Multicenter AIDS Cohort 
Study (MACS) and the AIDS Linked to the Intravenous Experience (ALIVE) study, 
cohort studies of men who have sex with men (MSM) and injection drug users (IDU), 
respectively, we determined whether self-reported adherence and HIV RNA suppression 
have changed between 2001 and 2011, concomitant with the availability of improved and 
simpler regimens. We further estimated the minimum adherence needed to achieve HIV 
RNA suppression in the population between 2006 and 2011, defining the cutoff as the 
level at which the odds of suppression was not significantly different than that observed 
with ≥95% adherence, and at which at least 80% were suppressed.  In both cohorts, the 
proportion of HAART users reporting ≥95% adherence, and those suppressing HIV RNA 
improved over time. In the MACS, greater than 80% suppression was observed with 80-
84% adherence and the odds ratio for suppression compared to those with ≥95% 
adherence was 1.43 (0.61, 3.33).  In the ALIVE study, only 71.4% were suppressed 
among those who reported ≥95% adherence. While in a population of MSM HAART 
users on newer HAART regimens, being 80% adherent to treatment is sufficient for viral 
load suppression, it may be necessary for IDUs on older HAART regimens to be more 
than 95% adherent to HAART.  Although all HIV-infected persons should be counseled 
to be 100% adherent, concerns related to non-adherence may be less of a barrier to 






Approximately 34 million people were living with HIV at the end of 2011.
1
  With 
the introduction of highly active antiretroviral therapy (HAART) in 1996, there was a 
significant decline in AIDS-related mortality, and a longer life expectancy among HIV-
infected persons treated with HAART.
2-6
 The treatment of HIV has evolved over the past 
two decades from highly toxic, complex regimens, to newer formulations with improved 
pharmacokinetics that are easier to administer.
7
  Effective treatment is defined by 
achieving low, undetectable plasma HIV RNA levels (copies/mL).
7
 HAART needs to be 
administered daily over the course of a patient’s lifetime in order to keep HIV RNA 
levels suppressed, decrease rates of resistance, and prevent progression to AIDS and 
HIV-related death.   
Researchers investigating the effectiveness of HAART found that 95% adherence 
or better was necessary for approximately 80% of the population to achieve viral load 
suppression.
8,9
 This high level of adherence has been challenging for many individuals 
due to barriers to adherence
7
 that include treatment complexity,
10,11
 patient-related high-
risk behaviors such as use of non-prescription drugs, lack of social support, and 
sociodemographic factors such as age and comorbidities.
12
 Individual responses to 
treatment such as tolerability, drug-resistance, durability of virologic and immunologic 
responses, and pharmacokinetic factors vary, and sometimes untreated symptoms due to 
suboptimal viral load suppression may impair subsequent adherence to HAART.
13
 There 
are negative consequences of requiring high levels of adherence.  First, physicians may 
be reluctant to prescribe HAART universally to patients early in the infection due to 
concerns about the ability to maintain adherence to HAART over time.
14 




patients on HAART, a significant amount of resources have been invested in improving 
adherence to HAART.
7
 Resource-intensive strategies to improve HAART adherence 
have included electronic reminders, administration of medications under supervised 
settings, self-monitoring, counseling,
15
 and adherence improvement strategies such as 
Directly Administered Antiretroviral Therapy (DAART)
16
 for drug users, and Sharing 
Medical Adherence Responsibilities Together (SMART for couples).
16
 In addition to the 
costs, these strategies are often administered only for fixed periods of time, and 




Given the improved pharmacokinetics of newer HAART regimens over therapies 
administered in the earlier treatment era, and concerns about the need to maintain high 
adherence, empirical data are needed to know whether viral load suppression is possible 
at lower levels of adherence at the population level.  A lower level of adherence required 
for effective treatment may alleviate the concerns noted above, result in earlier initiation 
of treatment in patients, and also enable physicians to determine which patients require 
in-depth counseling for adherence.  Improving access to, and consistent use of medicines 
by HIV-infected individuals would decrease their risk of transmitting the virus to others, 




This study aimed to determine whether the association between adherence and 
HIV RNA suppression has changed over time, and to estimate the minimum optimal 
cutoff of adherence for HIV RNA suppression.  The hypothesis was that the effectiveness 




copies/mL, does not require the near perfect levels of adherence (≥95%) as was required 
with earlier regimens.   
 
Methods 
We used longitudinal data collected prospectively between March 2001 and 
December 2011 from the participants in the Multicenter AIDS Cohort Study (MACS), 
and the AIDS Linked to the Intravenous Experience (ALIVE) study who reported using 
HAART between 2001 and 2011 for at least one visit.   
The MACS is an ongoing prospective study of HIV-1 infection among men who 
have sex with men (MSM) in the United States.
19
 A total of 6,992 men have been 
recruited since 1984 in 3 waves of recruitment: 5,622 men before 1991, 1,350 men in 
2001-03, and 20 men since 2010, in Baltimore, MD, Chicago, IL, Los Angeles, CA, and 
Pittsburgh, PA.
19
  Eligible persons had to be sexually active, 18 years or older, and free of 
an acquired immunodeficiency syndrome (AIDS)-defining illness, i.e., opportunistic 
infection or malignancy.
20
  Every six months, the study visits entail physical 
examinations, collection of blood for concomitant laboratory testing and storage, and 
standardized interviews to collect information on demographics, medical history, and 
behaviors. MACS study protocols were approved by institutional review boards at each 
study center, and informed consent was obtained from all participants.   
The ALIVE study is a prospective community-based cohort study of injection 
drug users (IDUs) in Baltimore, MD.
21
 A total of 2,946 IDUs were recruited initially 
through community outreach in 1988-1989.
21
 This was followed by three waves of 




followed over time since 1996.
17
  Eligible persons had to be 18 years or older, free of 
AIDS during initial recruitment waves, and have a history of injection drug use. Similar 
to the MACS, at each 6-month study visit, researchers collect information on 
sociodemographic characteristics, medical history, HIV risk behaviors (sexual and drug-
related), drug treatment, and collection of blood for concomitant laboratory testing and 
storage.  ALIVE study procedures were reviewed and approved by the institutional 
review board at the Johns Hopkins Bloomberg School of Public Health, and all 
participants provided written informed consent.  
In both cohorts, HIV RNA levels were determined using the Roche Ultrasensitive 
RNA PCR assay (Hoffman-LaRoche, Nutley, NJ, U.S.A.) with a detection limit of 50 
copies/ml, and CD4+ levels were quantified using standardized flow cytometry.
19, 21
  The 
Baltimore MACS site and the ALIVE study use the same laboratory for flow cytometry 
and HIV RNA quantification. 
 
Definition of HAART 
 HAART was defined using the DHHS guidelines as ‘a combination antiretroviral 
treatment regimen containing at least 3 antiretroviral drugs - 2 nucleoside reverse-
transcriptase inhibitor (NRTI) medications plus a protease inhibitor (PI), a non-




 Based on the type of HAART regimen used in the general population, we 




HAART, 2001 through 2005; and current HAART, 2006 through 2011. Date of HAART 
initiation was set as the visit date of the first HAART report. 
 
Study population  
Specifically, our study population was restricted to HIV-positive men and women 
who were on HAART from March 1, 2001 to December 31, 2011 (mid- and current eras). 
In addition, to examine trends in adherence and viral load over time, we further restricted 
the population to those contributing data from Jan 1, 2009 onwards. This latter restriction 
was implemented to avoid bias in temporal trends due to earlier attrition as a result of 
worse outcomes; for example, examining temporal trends by including those who 
developed AIDS and died before 2009, would result in different persons comprising 
calendar periods under study and bias the results. Only visits at which participants 
reported using HAART were included in the analysis.  
 
Outcomes and Exposures 
Adherence to HAART was defined using self-reported information collected at 
the study visits.  In the MACS, the participant was asked about his actual use of each 
antiretroviral medication over the four days prior to the study visit.  These responses were 
compared to the prescribed usage to determine adherence;  
 
Sum of the number of times the patient took the drug over a 4-day period                 * 100 
Sum of the number of times they were expected to take the drug each day * 4    




 As an exposure, adherence to HAART was treated as a categorical variable based 
on the distribution of adherence in the study population, and was also dichotomized as 
≥95% or less. As an outcome, adherence was treated as a continuous variable. In the 
ALIVE study, self-reported adherence data were collected and the adherence percent was 
calculated similar to the MACS, except that usage over a 3-day period was ascertained.  
Potential predictors of viral load suppression (<50 copies/mL) and adherence 
were sociodemographic and behavioral characteristics reported for the 6 months prior to 
when adherence and HIV RNA were measured. These included age, race, annual income 
(<$10,000 versus ≥$10,000), insurance status (private, public, none), current injection 
drug use, non-injection drug use (including cocaine, crystal methamphetamine, 
marijuana, heroin, poppers), current smoking, and moderate-heavy alcohol intake 
(defined as 3-4 drinks/day or more for more than once a month or ≥5 drinks/day for less 
than once a month) compared to lower quantities. Treatment and disease characteristics 
included number of antiretrovirals, CD4 cell count, and self-reported depressive 
symptoms (measured using the Centers for Epidemiologic Studies Depression Scale 
(CES-D)).
23
  Persons with scores greater than 16 on the CES-D were classified as having 
symptoms of depression.
23
 Both CD4 cell count and CES-D scores were lagged to the 
previous visit.  In the ALIVE study, additional variables included homelessness, 
incarceration (≥1 week), and the length of the visit interval. We also controlled for the 
type of HAART regimen (NNRTI-based, PI-based, INSTI-based, and single pill) in both 
cohorts.  Gaps in treatment were calculated for both cohorts since they were likely to 
impact the association between adherence and viral load suppression. Gaps in treatment 




In addition to being included as a confounder in the analysis, an interaction term between 
adherence and having one or more gaps in treatment was included to check for potential 
effect modification.   
 
Statistical Methods 
 The 2 cohorts were analyzed separately since they represented two distinct risk 
groups (MSM and IDU), which could modify associations, and also because they 
presented with very different distributions of adherence.  We restricted the analysis to 
person-visits with non-missing covariates, representing about 95% of the sample. 
Exclusion of these person-visits did not alter any trends or results from univariate 
analysis that used the full population. In both cohorts, for those with first HAART visits 
after 2006 with missing values in lagged CD4 cell counts, we used the CD4 count at that 
visit (MACS: 0.1%, ALIVE: 6.9%).  The average change in adherence over time was 
determined at the population and individual levels. Linear mixed effects models with 
random intercept and slope, adjusted for confounders were used to study the effect of 
time on adherence. Adherence was modeled as a continuous outcome and two models 
were fit. In the first model, time was modeled as a dichotomous variable (<2006 and 
≥2006), and in the second model, time was modeled as a discrete variable, using 2-year 
intervals. The fixed component of the model, the β coefficients, were used to determine 
the average change in adherence accounting for individual correlation between 
observations. The variance of the random slope, σ2
2
, estimated using maximum 
likelihood, was used to determine between-person changes over time. A likelihood ratio 




To initially examine whether the proportion suppressing HIV RNA changed over 
time among those not fully adherent, we graphically depicted the proportion suppressed 
from 2001-2011 among those with <95% adherence. The best fit for the relationship 
between proportion suppressed and time was determined based on the Akaike 
Information Criterion (AIC) statistic.  To define the minimum optimal adherence cutoff 
in the population, two criteria had to be met: 1) since historically, 80% of treated HIV-
infected persons with ≥95% adherence had suppressed viral load,
8,9
 this level had to be 
achieved; and 2) the odds of viral load suppression at the cutoff could not be statistically 
different from that observed in the population with ≥95% adherence. Since we were 
interested in defining this cutoff for adherence to current HAART regimens, we restricted 
this analysis to data from 2006 onwards.  The proportion suppressed was plotted 
according to categories of adherence based on the observed distribution by cohort. 
Logistic regression models with viral load suppression as the outcome, and adherence 
percent as the primary exposure controlling for repeated measures over time and 
adjusting for confounders were used to compare the odds of suppression at the adherence 
category to that observed in the reference category (≥95% adherence).  
All analyses were performed using SAS 9.2 (Cary, North Carolina, USA) and 
STATA 12.1 (College Station, Texas, USA).  A p-value threshold of 0.05 was used to 










 A total of 1,215 MACS participants contributed 12,310 person-visits, and 337 
ALIVE participants contributed 2,188 person-visits in 2001-2011, of whom 1,026 and 
197, respectively, contributed data since 2009. After excluding 5% of the person-visits 
due to missing covariates in the MACS, the study population consisted of 11,678 person-
visits contributed by 1,194 participants, of which 1,006 were seen since 2009. The 
missing data by covariates were: alcohol use (1.8%), smoking (1.6%), non-injection drug 
use (1.9%), and depression (2.3%). Characteristics of the study populations seen since 
2009 according to adherence are described in Table 2.1. Supplemental Table 2.1 shows 
the characteristics of all participants, compared to those seen since 2009.  In the MACS, 
adherence was significantly associated with higher income, having private insurance, 
abstinence from injection and non-injection drug use, a higher CD4 count, and virologic 
suppression. In the ALIVE study, those with ≥95% adherence had a significantly lower 
proportion of alcohol users, and current injection and non-injection drug users. The 
overall proportion suppressed was also significantly higher for visits with ≥95% 
adherence compared to visits with <95% adherence.  
 In the MACS, the use of multiple pill regimens which were PI-based and NNRTI-
based declined from 51% and 39%, respectively in 2006, to 36% and 16%, respectively 
in 2011. Concomitantly, the use of newer regimens –single pill, and INSTI-based has 
increased steeply over time from 5.7% and 0% in 2006 to 27% and 19% in 2011, 
respectively. In the ALIVE study, the use of PI-based and NNRTI-based regimens also 




The use of single pill and INSTI-based regimens rose from 0% to the current use of 21% 
and 12% in 2011.   
 
Adherence over time 
As shown in Figure 2.1, the proportion reporting 100% adherence increased in 
both cohorts from 2001 through 2011. Restricting the population to those seen from 
2009-2011, the increases in reporting 100% adherence from 2001-2011 was 84% to 90%, 
and 87% to 92% in the MACS and ALIVE study, respectively. Table 2.2 shows the 
results from linear mixed models used to examine the change in adherence over time.  
There was an increase in the average adherence over time in the MACS after accounting 
for within-person changes - an 11% increase in average adherence every two years, and a 
33% increase in average adherence in the latter era compared to the earlier era. Adjusting 
for confounders attenuated the change in adherence over time in the population.  There 
was significant variability (σ2
2
=3.3 (2.8, 3.9)) in the change of adherence over time.  In 
the ALIVE study, there was a 14% increase in the average adherence every two years, 
and a 22% increase in the adherence in the latter era compared to the earlier era using the 
results from the adjusted model. There was significant variability in the change of 
adherence over time (σ2
2
=3.1 (1.3, 7.3)), and high variability in this trajectory in the 
ALIVE (Root Mean Square error: 11.69) as seen in Figure 2.1.  
Almost 25% of HAART users in the MACS reported at least one gap in treatment 
and 12.9% reported multiple gaps of HAART such that HAART use was not reported for 




reported at least one gap in treatment, and 53.4% reported multiple gaps such that 
HAART use was not reported for 34.6% of 3,426 person-visits following initiation. 
 
HIV RNA suppression 
Overall, 79.9% of the MACS person-visits had undetectable HIV RNA since 
2001 (Supplemental Table 2.1), and the proportion suppressing HIV RNA in the MACS 
participants with <95% adherence increased since 2001, and ranged between 75% and 
79% since 2006 (Figure 2.2). For the MACS, the model with time included as a 
piecewise linear term (AIC: 130.1) was a better fit than time modeled as a linear term 
(AIC: 138.2), or as a polynomial term (AIC: 139.2). For the ALIVE study, the model 
with time included as a linear term (AIC: 32.24) was a better fit than time modeled as a 
quadratic term (AIC: 33.74). 
 
Minimum Optimal Adherence  
In the current era (2006-11), the proportion suppressing HIV RNA increased with 
increasing adherence (Figure 2.3). At adherence levels between 80% and 84%, the 
proportion suppressing HIV RNA was greater than 80% (83.5%). For those with ≥95% 
adherence, 85.1% had undetectable HIV RNA levels. Random-effects logistic regression 
models with viral load suppression as outcome, adjusted for age, number of drugs, 
recreational non-injection drug use, alcohol use, race, smoking, lagged CD4 cell count, 
and type of HAART, confirmed that at adherence levels between 80% and 84%, the odds 
of viral load suppression were not significantly different than that among those with 




among those with a gap in treatment (OR: 0.61 (0.55, 0.67)), there was no statistically 
significant interaction between adherence and having at least one gap in treatment.   
In the ALIVE study, we did not observe a minimum optimal adherence cutoff 
below 95% because less than 80% of the population was suppressed among those with 
≥95% adherence (71.4%). Further, the adjusted odds of viral load suppression were 
appreciably lower with levels of adherence <95%, compared to the odds of viral load 
suppression at ≥95% adherence, although not statistically significant. Among those 
reporting ≥95% adherence, those who were currently injecting drugs were less likely to 
suppress HIV RNA than those not injecting drugs (55.4% vs. 74.8%, P<0.001). Similar to 
that seen in the MACS, the odds of suppression was significantly lower among those with 
a gap in treatment (OR: 0.50 (0.36, 0.69)), and there was no statistically significant 
interaction between adherence and having at least one gap in treatment.   
 
Discussion 
In these prospective cohorts of HIV-infected MSM and IDUs, there was an 
observable increase in the proportion reporting ≥95% adherence to HAART between 
2001 and 2011. Our data are consistent with the hypothesis that adherence to HAART 
has become easier over time with newer and simpler HAART formulations.  This concurs 
with previous studies reporting increased ease of adherence to once-daily regimens 
compared to multi-dose regimens.
13,24,25 
 Both cohorts reported an increase in the use of 





Newer drugs have also made viral load suppression possible at adherence levels 
lower than the 95%. Second-generation PIs (e.g., darunavir and tipranavir), NNRTIs 
(e.g., rilpivirine, etravirine), and newer classes such as INSTIs (e.g., raltegravir), enable 
durable viral load suppression with generally easier administration owing to high potency 
and improved pharmacokinetic profiles.
26,27
 Importantly, they also have improved 
tolerability profiles, which may lead to better adherence. While newer HAART 
formulations may now be easier to administer, they also do not necessarily require 
consistently high levels of adherence for viral load suppression as suggested in previous 
studies.
26-28
   
However, the population-level benefit of these newer formulations may be limited 
since some marginalized groups are not being prescribed these drugs as often as others.  
In our study, while more than 50% of MACS participants reported recent use of a newer 
HAART formulation, fewer than 35% of ALIVE participants were on these HAART 
regimens in 2011.  This finding is consistent with a previous study by Mehta et al which 
reported that IDUs in Baltimore were initiating care at more advanced disease stages, and 
were not receiving newer HAART regimens.
29
 The low proportion of suppressed visits in 
the ALIVE may thus in part be attributed to drawbacks of using older HAART regimens 
with shorter half-lives, increased pill burden, poor tolerability and drug resistance.  
However, it is also likely that the observation of a lower overall viral load suppression 
rate in the ALIVE study reflected a higher frequency of treatment gaps and greater 
barriers to consistent HAART use including frequent homelessness, incarceration, 






 may also have led to the development of drug resistance and subsequently 
higher rates of treatment failure.  
Our data suggest that adherence levels as low as 80% to 84% may be sufficient 
for viral load suppression in populations using newer HAART formulations.  This is 
consistent with literature suggesting that chronically ill patients using 80% of their 
medications, are generally categorized as being adherent to their treatment.
31
 However, 
this message should be interpreted with caution. While our study points to lower 
adherence levels for effectiveness than previously established, the goal is not to 
encourage patients to be less adherent to medications. It is important for HIV providers to 
continue emphasizing the importance of 100% medication adherence. However, keeping 
in mind that some patients may not be as adherent to their medications due to specific 
barriers, they can divert resources for comprehensive counseling sessions towards 
patients with barriers to adherence.  
Important predictors of high adherence to HAART and viral load suppression in 
the MSM cohort were found to be older age, non-Black race, higher CD4 count, and non-
use of alcohol, cigarettes or recreational non-injection drugs, consistent with previous 
studies evaluating predictors of adherence to HAART in the MACS, and in other 
populations.
10,21,32-34
 Similarly, in the ALIVE study, older age, non-use of alcohol, 
cigarettes, recreational injection and non-injection drugs, and not being incarcerated, 








As stated earlier, it was not possible for us to confirm a minimum optimal 
adherence cutoff lower than 95% for IDUs in the ALIVE. Although the lack of statistical 
significance in ORs could be attributed to the small sample size, only 71.4% were 
suppressed among those with ≥95% adherence, which is less than optimal, and lower, 
when compared to that observed in previous literature.
8
 In addition to use of older 
regimens and low retention in treatment, this study population consisted of low-income 
individuals with a high proportion of substance use. When stratified by current injection 
drug use, significant differences were observed in the proportion of individuals 
suppressed at ≥95% adherence. Therefore, rate-limiting steps to achieving optimal 
adherence in this population may be patient-related behaviors, in addition to physician 
prescribing behaviors.   
The use of self-reported adherence is a limitation to the study. Self-reported 
adherence is associated with recall error and social-desirability bias, which may lead 
participants to over-estimate their actual adherence.
34
 Additionally, self-reported 
adherence may be less reliable in a population of IDUs.
38 
This may have led to the 
relatively low proportion of suppression among those reporting ≥95% adherence in the 
ALIVE study. Another possible explanation for the lower level of suppression achieved 
by adherent ALIVE participants may be drug resistance. However, these data were not 
available. Another limitation may be misclassification of the antiretroviral medications 
used by the participants. Although cross-checking with medical records would address 
the reliability of self-report, it would not assess the validity of the actual use. Given that 







There were several strengths associated with this study as well.  Both the MACS 
and the ALIVE are long-standing cohort studies examining the natural and treated 
histories of HIV in two important risk groups in the United States – MSM and IDU – that 
use standardized methods for data collection, and have relatively low attrition. Although 
self-reported data for adherence are associated with biases as described earlier, an 
important strength of our data is that persons were not reporting their adherence to their 
providers. This may have decreased the social desirability bias to some extent, since 
providers are more likely to counsel patients with sub-optimal adherence, and make 
changes to their treatment regimen. Participants reported their adherence before their 
viral load test, and therefore, in addition to temporality of the relationship, there was no 
bias in the reporting of adherence due to knowing the HIV RNA test outcome.   
 
Conclusion 
In summary, in the current era of HIV treatment, in addition to the ease of use of 
newer formulations which make high levels of adherence easy to achieve, improved 
formulations have made viral load suppression possible at lower adherence levels, which 
is consistent with evidence from recent studies.
7,40
 While in a population of MSM 
HAART users on newer HAART regimens, being 80% adherent to treatment may be 
sufficient for viral load suppression, IDUs on older HAART regimens may need to be 
more than 95% adherent to HAART.  In a population with more limited access and 
poorer engagement in care, the prescription of newer drugs may potentially help alleviate 
the barriers to treatment, and improve overall treatment outcomes. Future studies should 




similar to that observed in the MSM population if given the same opportunity for newer 
regimens. 
HIV providers should therefore not let concerns regarding adherence assume 
primacy and hinder the appropriate use of modern HAART regimens broadly at earlier 
stages of HIV disease. In parallel, retention and engagement in care should continue to be 
a primary objective, and this together with more universal prescribing patterns, will 
potentially improve individual outcomes and indirectly alleviate disease burden in the 
population. While HIV providers should continue to urge patients to achieve perfect 
adherence, comprehensive adherence counseling support may be best targeted to persons 


















1. Global Health Observatory (GHO). World Health Organization. Available at: 
http://www.who.int/gho/hiv/en/. Accessed: Jun 5, 2013. 
2. Chu C, Umanski G, Blank A, Meissner P, Grossberg R, Selwyn PA. Comorbidity-
Related Treatment Outcomes among HIV-Infected Adults in the Bronx, NY. J 
Urban Health. 2011;88(3): 507–516. 
3. Adeyemi OM, Badri SM, Max B, Chinomona N, Barker D. HIV infection in older 
patients. Clin. Infect Dis. 2003;36:1347. 
4. Manfredi R. HIV infection and advanced age emerging epidemiological, clinical, 
and management issues. Ageing Research Reviews. 2004;3(1):31-54. 
5. Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-
AIDS related morbidity. BMJ. 2009; 338:288-292. 
6. Wada N, Jacobson LP, Cohen M, French A, Phair J, Muñoz A. Cause-Specific 
Life Expectancies After 35 Years of Age for Human Immunodeficiency 
Syndrome-Infected and Human Immunodeficiency Syndrome-Negative 
Individuals Followed Simultaneously in Long-term Cohort Studies, 1984–2008. 
Am J Epidemiol. 2013;177 (2):116-125. 
7. Kobin BA, Sheth NU. Levels of Adherence Required for Virologic Suppression 
Among Newer Antiretroviral  Medications. Ann Pharmacother. 2011;45:372-9. 
8. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy 
and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30. 
9. Nelson M, Girard PM, DeMasi R, et al. Suboptimal adherence to 




lopinavir/ritonavir in treatment-naïve HIV-infected patients: 96 week ARTEMIS 
data. J Antimicrob Chemother. 2010; 65:1505-9. 
10. Cooper V, Horne R, Gellaitry G, et al. The impact of once-nightly versus twice-
daily dosing and baseline beliefs about HAART on adherence to efavirenz-based 
HAART over 48 weeks: the NOCTE study. J Acquir Immune Defic 
Syndr. 2010;53(3):369-77. 
11. Chesney M.  Adherence to HAART regimens. AIDS Patient Care 
STDS. 2003;17(4):169-77 
12. Silverberg MJ, Leyden W, Horberg MA,  DeLorenze GN, Klein D, Quesenberry 
CP Jr. Older age and the response to and tolerability of Antiretroviral therapy. 
Arch Intern Med. 2007;267:684-691. 
13. Gulick RM. Adherence to antiretroviral therapy: how much is enough. Clin Infect 
Dis. 2006; 43 (7):942-904. 
14. Westergaard RP, Ambrose BK, Mehta SH, Kirk GD. Provider and clinic-level 
correlates of deferring antiretroviral therapy for people who inject drugs: a survey 
of North American HIV providers. J Int AIDS Soc. 2012;15(1):10. 
15. Zaric GS, Bayoumi AM, Brandeau ML, Owens DK. The Cost-Effectiveness of 
Counseling Strategies to Improve Adherence to Highly Active Antiretroviral 
Therapy among Men Who Have Sex with Men. Med Decis Making. 2008;28:359–
376. 
16. Good Evidence Medication Adherence Interventions. Available at: 
http://www.cdc.gov/hiv/topics/research/prs/ma-good-evidence-interventions.htm. 




17. Westergaard RP, Hess T, Astemborski J, Mehta SH, Kirk GD. Longitudinal 
changes in engagement in care and viral load suppression for HIV-infected 
injection drug users. AIDS. 2013;27(16):2559-66. 
18. Monitoring HIV Care in the United States. Available at: 
http://www.iom.edu/~/media/Files/Report%20Files/2012/Monitoring-HIV-Care-
in-the-United-States/MonitoringHIV_rb.pdf. Accessed: Jun 20, 2013. 
19. Kaslow RA, Ostrow DG, Detels R, Phair JP, Polk BF, Rinaldo CR Jr. The 
Multicenter AIDS Cohort Study: rationale, organization, and selected 
characteristics of the participants. Am J Epidemiol. 1987;126:310-8. 
20. CDC.1993 Revised classification system for HIV infection and expanded 
surveillance case definition for AIDS among adolescents and adults. MMWR 
1992;41[No. RR-17]. Available at: 
http://www.cdc.gov/mmwr/preview/mmwrhtml/00018871.htm. Accessed: Jun 10, 
2014.  
21. Vlahov D, Anthony JC, Munoz A, et al. The ALIVE study, a longitudinal study of 
HIV-1 infection in intravenous drug users: description of methods and 
characteristics of participants. NIDA Res Monogr. 1991;109:75–100. 
22. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the 
use of antiretroviral agents in HIV-1-infected adults and adolescents. Department 
of Health and Human Services. Available at:  
http://www.aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. 




23. Radloff LS. The CES-D Scale: A Self-Report Depression Scale for Research in 
the General Population. Applied Psychological Measurement. 1977; 1: 385-401. 
24. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and 
efavirenz vs. Zidovudine, lamivudine and efavirenz for HIV. N Eng J Med. 2006; 
354:251–260. 
25. Cooper V, Horne R, Moyle G, Fisher M, The SWEET study group. Simplification 
with easier emtricitabine and tenofovir (SWEET): results of a 48 week analysis of 
patients’ perceptions of treatment and adherence. The XVII International AIDS 
Conference. Mexico City, Mexico. August 3–8, 2008 [abstract]. 
26. Hughes CA, Robinson L, Tseng A, Macarthur RD. New antiretroviral drugs: a 
review of the efficacy, safety, pharmacokinetics, and resistance profile of 
tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir. Expert 
Opin. Pharmacother. 2009; 10(15):2445-2466. 
27. Shuter J, Sarlo JA, Kanmaz KA, Rode RA, Zingman BS. HIV-infected patients 
receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of 
virologic suppression despite adherence rates below 95%. J Acquir Immune Defic 
Syndr. 2007; 45(1): 4-8. 
28. Maggiolo F, Airoldi M, Kleinloog HG, et al. Effect of Adherence to HAART on 
Virologic Outcome and on the Selection of Resistance-Conferring Mutations in 
NNRTI- or PI-Treated Patients. HIV Clin Trials. 2007;8(5):282-92. 
29. Mehta SH, Kirk GD, Astemborski J, Galai N, Celentano CD. Temporal Trends in 
Highly Active Antiretroviral Therapy Initiation among Injection Drug Users in 




30. Kavasery R, Galai N, Astemborski J, et al. Nonstructured treatment interruptions 
among injection drug users in Baltimore, MD. J Acquir Immune Defic Syndr. 
2009; 50(4):360-6 
31. Ho MP, Bryson CL, Rumsfeld  JS. Medication adherence: its importance in 
cardiovascular outcomes. Circulation. 2009; 119: 3028-3035.  
32. Kleeberger CA, Phair JP, Strathdee SA, Detels R, Kingsley L, Jacobson LP. 
Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the 
Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. 2001;26(1):82-
92. 
33. Kleeberger CA, Buechner J, Palella F, et al. Changes in adherence to highly 
active antiretroviral therapy medications in the Multicenter AIDS Cohort 
Study. AIDS. 2004;18(4): 683-688.    
34. Lazo M, Gange SJ, Wilson TE, et al.  Patterns and predictors of changes in 
adherence to highly active antiretroviral therapy: longitudinal study of men and 
women. Clin Infect Dis. 2007;45(10):1377-1385. 
35. Vlahov D, Celentano DD. Access to highly active antiretroviral therapy for 
injection drug users: adherence, resistance, and death. Cad Saude 
Publica. 2006;22:705-718. 
36. Malta M, Magnanini MMF, Strathdee SA, Bastos FI. Adherence to Antiretroviral 





37. Kerr T, Palepu A, Barness G, et al. Psychosocial determinants of adherence to 
highly active antiretroviral therapy among injection drug users in Vancouver. 
Antivir Ther. 2004;9(3):407-14. 
38. Kerr T, Hogg RS, Yip B, et al. Validity of Self-Reported Adherence Among 
Injection Drug Users. J Int Assoc Physicians AIDS Care (Chic). 2008;7(4):157-9. 
39. Cole SR, Jacobson LP, Tien PC, Kingsley L, Chmiel JS, Anastos K.  Using 
Marginal Structural Measurement-Error Models to Estimate the Long-term Effect 
of Antiretroviral Therapy on Incident AIDS or Death. Am J Epidemiol. 
2010;171:113–122. 
40. Bangsberg D. Less Than 95% Adherence to Nonnucleoside Reverse-
Transcriptase Inhibitor Therapy Can Lead to Viral Suppression. Clin Infect Dis. 

























P-value Adherence <95% 
(N person-visits= 







Age, mean (SD) 47.6 (8.4) 49.4 (8.7) <0.01 48.9 (6.1) 49.9 (6.6) 0.06 
Black 33.5 24.8 <0.01 96.5 95.9 0.49 





















































 32.0 30.3 0.20 79.2 75.6 0.35 
Alcohol consumption
&
 15.0 13.5 0.20 46.7 32.4 <0.01 
Current injection drug use 2.8 1.6 0.01 32.0 17.4 <0.01 
Non-injecting recreational 
drug use  
54.1 47.0 <0.01 26.4 17.8 <0.01 






















P-value Adherence <95% 
(N person-visits= 







Viral load (% suppressed) 70.1 81.2 <0.01 52.8 67.2 <0.01 
Depression status (%)^ 23.3 20.6 0.03 37.8* 29.1* 0.04 
δ 
Population restricted to participants seen since 2009; 
&
MACS: moderate-to-heavy consumption, ALIVE: drank >1 day/week; ^CESD (≥16) *2006-
2011; 
#
Current smoking (including occasional smoking); 
¶






Table 2.2. Change in adherence over time (2001-2011) 






































Adjusted for age, race, alcohol use, smoking, type of HAART, and non-injection drug use 
#



























































































ALIVE:            All persons (Person-visits=2,188) 





               Best fit line 
(those seen since 2009)                  
Bars represent 95% CI 
              
MACS:               All persons (Person-visits=11,678) 
                            Those seen since 2009  
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                          Best fit line 
     Bars represent 95% CI 












































OR: 0.47 (0.25, 
0.89) 









MACS (Person-visits=6,907)  
Proportion suppressed in 
reference group (≥95% 
adherence): 85.1% 
0-49 50-74 75-94
Adherence percent category 
OR: 0.33 (0.10, 
1.10) 
OR: 0.56 (0.26, 
1.23) 
OR: 0.76 (0.32, 
1.78) 
ALIVE (Person-visits=1,329) 
Proportion suppressed in 
reference group (≥95% 
adherence): 71.4% 
         Actual line 
           Best fit line 
Bars represent 95% CI 
Odds Ratios for HIV RNA suppression obtained from a random-effects 
logistic regression model comparing suppression at the adherence 
category to adherence ≥95%, and adjusted for age, race, alcohol use, 
non-injection drug use, smoking, type of HAART, and CD4 count from 
previous visit 
Odds Ratios for HIV RNA suppression obtained from a random-
effects logistic regression model comparing suppression at the 
adherence category to adherence ≥95%, and adjusted for age, sex, 
injection drug use, alcohol use, smoking, CD4 count from previous 





Appendix Table 2.1. Study Population Characteristics (2001-2011): comparing everyone against those seen since 2009 
Characteristics 


















Age, mean (SD) 49.1 (8.8) 49.2 (8.6) 0.26 49.4 (6.4) 49.8 (6.5) 0.05 
 Black  25.8 25.8 1.0 95.7 96.0 0.64 



















































 31.0 30.5 0.41 75.8 76.0 0.88 
Alcohol consumption
&
 13.7 13.7 1.0 33.2 34.0 0.60 
Current injection drug use  1.8 1.7 0.57 20.5 19.0 0.24 
Non-injecting recreational 
drug use  
48.1 47.8 0.65 18.5 18.7 0.87 
CD4 count at visit 
(cells/mm
3
), mean (SD) 
580.3 (279.6) 590.6 
(277.0) 
<0.05 361.5 (247.0) 375.5 (240.4) 0.25 





MACS: moderate-to-heavy consumption, ALIVE: drank >1 day/week; ^ CESD (≥16) *2006-2011; 
#
Current smoking (including occasional smoking); Italics 
denotes statistical significance 
 
Depression status^ 21.3 20.9 0.46 30.3* 29.9* 0.82 




Appendix Table 2.2. Odds Ratios for viral load suppression at different adherence 
levels in the MACS (2006-2011) 
























































*Adjusted for adjusted for age, race, type of HAART, non-injection drug use, alcohol use, smoking, and 

















Appendix Table 2.3. Odds Ratios for viral load suppression at different adherence 




between 50% & 
74% 
Adherence between 
75% & 94% 
Crude 0.26 (0.08, 0.89) 0.49 (0.22, 1.06) 0.80 (0.34, 1,88) 
Adjusted* 0.33 (0.10, 1.10) 0.56 (0.26, 1.23) 0.76 (0.32, 1.78) 
*Adjusted for age, gender, injection drug use, alcohol use, smoking, CD4 count from previous visit, non-




Appendix Figure 2.1. HAART regimen type by calendar year (2006-2011) 
 
 








































































ALIVE (N person-visits=1,329) 
PI 







Adherence and HIV RNA Suppression in the Current Era of Highly Active 








Background: We examined trends in adherence to highly active antiretroviral therapy 
(HAART) and HIV RNA suppression, and estimated the minimum cutoff of adherence to 
newer HAART formulations needed for HIV RNA suppression by regimen type. 
Methods:  We used VA pharmacy dispensing data from the Veterans Aging Cohort 
Study Virtual Cohort between October 2000 and September 2010, and defined adherence 
as the duration of time the patient had the medications available, relative to the total 
number of days between refills for all antiretrovirals in a year. Temporal trends in 
adherence and viral load suppression were examined by the patient’s most frequently 
used HAART regimen in the year. The minimum needed adherence was defined as the 
level at which the odds of suppression was not significantly different than that observed 
with ≥95% adherence using repeated measures logistic regression.  
Results: 21,865 HAART users contributed 82,217 person-years of follow-up. There was 
a significant increase (ptrend<0.001) in the proportion virally suppressed even among those 
with <95% adherence (2001: 38% to 2010: 84%) and the trend was similar when 
restricting to their first HAART regimen. For NNRTI multi-pill users, the odds of 
suppression did not differ for 85-89% adherence compared to those with ≥95% 
adherence, odds ratios: 0.82 (0.64,1.04), but for PI users, the odds of suppression 
significantly differed if adherence levels were <95% compared to ≥95% adherence.   
Conclusions: Although all HIV-infected persons should be instructed to achieve perfect 
adherence, concerns of slightly lower adherence should not hinder prescribing new 






Over the past decade, the proportion of individuals on highly active antiretroviral 
therapy (HAART) who achieve HIV RNA suppression has increased dramatically.
1
  This 
success has been attributed to improved medication adherence due to decreased HAART 
toxicity, fixed-dose combination pills, and simplified dosing strategies.
2,3
   
With improved second-generation formulations of non-nucleoside reverse 
transcriptase inhibitors (NNRTIs) (e.g., rilpivirine, etravirine), protease inhibitors (PIs) 
(e.g., darunavir, atazanavir), and newer classes like integrase strand transfer inhibitors 
(INSTIs) (e.g., raltegravir), levels of adherence as those required with early HAART 
regimens (i.e., ≥95%),
4,5
 may not be needed for maximal treatment effectiveness. A better 
understanding of the levels of adherence needed for effective treatment in the current era 
of HAART could further inform clinical care, and also alleviate provider concerns about 
prescribing HAART to patients with barriers to adherence at early stages of HIV 
infection.
6
   
We sought to determine whether adherence to HAART and HIV RNA 
suppression have changed over time, and estimate the minimum optimal adherence level 
for HIV RNA suppression by HAART regimen type using data from a large, population-




The analysis used longitudinal pharmacy refill data collected prospectively from 




Virtual Cohort (VACS VC) from October 1, 2000 to September 30, 2010. Details of the 
VACS VC have been previously described.
7
 Laboratory and clinical data, and outpatient 
prescriptions for each subject were obtained by linking Immunology Case Registry, and 
Pharmacy Benefits Management Registry records, respectively.
8
 HAART was defined 
using DHHS guidelines.
9
 Only person-years in which HAART was used for at least 180 
days in the year were included.  
 For each person-year, we used the regimen most frequently refilled to classify 
HAART as NNRTI-based, PI-based (including users of PIs, and both NNRTIs and PIs), 
INSTI-based, or 3 nucleoside reverse transcriptase inhibitors (NRTI) containing abacavir 
or tenofovir. We classified regimens as being single versus multi-pill, and whether 
administered once-daily versus twice-daily.   
 
Outcomes and Exposures 
Since HIV RNA levels were determined using assays with varying detection 
limits,
8
 we used values of <400 copies/mL as suppressed viral load, and used the last HIV 
RNA test of the year for analyses. Sustained suppression was examined among those with 
multiple viral load measurements in a year and was defined as having undetectable levels 
following their first measurement if suppressed.  
We calculated adherence to HAART using the medication possession ratio 
defined by Steiner and colleagues
10
 which measures the duration of time the patient had 
the medications available, relative to the total number of days between refills. This was 
calculated for each person-year that contained at least one refill as follows: 
∑ 𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑑𝑎𝑦𝑠 𝑠𝑢𝑝𝑝𝑙𝑖𝑒𝑑 𝑤𝑖𝑡ℎ 𝑑𝑟𝑢𝑔 𝑖𝑛 𝑎 𝑦𝑒𝑎𝑟𝐴𝑅𝑉𝑠






We excluded stockpilers (20.2% of study population), defined as person-years with a 
refill frequency exceeding the scheduled dosing interval by more than 5% since the 
Steiner algorithm was not validated in this subgroup.
8,11
  
    Potential confounders of viral load suppression and adherence included 
sociodemographic, behavioral, disease and treatment characteristics. Fixed characteristics 
included race, smoking, and geographical location obtained at the first time seen after 
October 1, 2000 (baseline). Time-varying factors included alcohol abuse, drug abuse, and 
major depression recorded using ICD-9 diagnosis codes, and for each year, the number of 
antiretrovirals used, number of days in possession of HAART regimens, regimen type, 
time since first HAART initiation, and mean CD4 cell count.  
 
Statistical methods 
 We graphically depicted temporal trends of adherence, suppression, regimen type 
and dosing frequency from 2001-2010. The change in adherence over time was 
determined using linear mixed effects models with adherence percent as outcome, 
accounting for repeated measures over time, and adjusting for confounders. In sensitivity 
analysis, we restricted the population to: a). those who were in follow-up after Jan 1, 
2009 (i.e., including those starting before or after 2009, but in follow-up between 2009 
and 2010) to avoid a biased temporal trend due to earlier attrition of those with worse 
outcomes from low adherence, and b). the person-years on the first HAART regimen, 
since switching regimens may not be random, and may result from lower adherence and 




 We defined the minimum optimal adherence as the level of adherence at which 
the odds of suppression were not statistically different from that observed among those 
with ≥95% adherence. To focus on newer HAART regimens, we restricted this analysis 
to data from 2006 onwards and used logistic regression with viral load suppression as the 
outcome, and adherence percent as the primary exposure controlling for repeated 
measures over time and adjusting for confounders. Since characteristics informing 
prescribing patterns may affect adherence and HIV RNA suppression, we adjusted for 
this possible confounding by indication using propensity scores to weight the repeated 
measures logistic regression model. The propensity score for using an NNRTI-based 
regimen was determined by logistic regression which included age, race, geographical 
location, time since first HAART initiation, and CD4 count, HIV RNA suppression, drug 
abuse, alcohol abuse, and major depression diagnosis lagged to the previous year. 
Weights were generated as the average treatment effect for the treated (ATT), and 
included in the repeated measures logistic regression model as a covariate.  
ATT,  T= E[Yi(1)-Yi(0)|Ti=1]; Y=NNRTI use (yes=1 and no=0) 
In sensitivity analyses, we varied the restriction on the number of days on HAART in the 
year to 270 days and 330 days.   
  All analyses were performed using SAS 9.2 (Cary, North Carolina, USA) and 







Study population characteristics  
 A total of 21,865 HAART users contributed 82,217 person-years between 
October 1, 2000 and September 30, 2010. At baseline, the mean age was 45.7 (standard 
deviation (SD): 9.9) years, 98% were male, and 46.5%, 41.6%, and 7.6% were black, 
white and Hispanic, respectively (Table 3.1). Almost 60% were current smokers, 47% 
used VA facilities in the South, 23.3% in the Northeast, and less than 20% in the 
Midwest and West, respectively.  Unadjusted, those with ≥95% adherence were older, 
less likely to have abused alcohol or drugs, and had higher CD4 cell counts compared to 
those with lower adherence during follow-up. 
 The use of PI-based and NNRTI-based multi-pill regimens declined between 2001 
and 2010 from 65% to 43%, and 33% to 16%, respectively (Figure 3.1). Single pill 
regimen use and INSTI-based regimen use increased steeply since 2006 from 1% to 29%, 
and 0% to 11% respectively, in 2010. All the participants on single pill regimens were 
using efavirenz(EFV)/tenofovir disoproxil fumarate(TDF)/emtricitabine(FTC). 
 
Adherence 
 The proportion of HAART users with ≥95% adherence increased marginally from 
37% in 2001 to 42% in 2010 (Figure 3.2). More users of NNRTI-based regimens were 
≥95% adherent than users of PI-based regimens. Up to 2006, multi-pill regimens were 
associated with significantly better adherence if taken once-daily versus twice-daily 
(Appendix Figure 3.1). From 2006 onwards, users of single pill regimens had better 




accounting for within-person correlation, there was a 13% increase in the adherence 
every two years on average (Appendix Table 3.1).  
 
HIV RNA suppression 
 Among those with <95% adherence, the proportion suppressed increased over 
time from 38% in 2001 to 84% in 2010 (ptrend<0.001) (Figure 3.3A), and did not 
appreciably differ when restricted to persons seen since 2009 or on their first HAART 
regimen. This increase in viral suppression was observed even among those with 75-79% 
adherence (Figure 3.3B). Across all years, HAART users had an average of 3 HIV RNA 
tests per year, and the proportion with sustained viral load increased over time from 
77.5% in 2001 to 92.0% in 2010. This trend occurred across regimen types but at 
different levels (Appendix Figure 3.2).  
 
Minimum optimal adherence 
 Overall, HIV RNA suppression for persons with 90-94% adherence did not differ 
from those with ≥95% adherence (odds ratios (OR): 1.05 (0.91, 1.21)) (Appendix Table 
3.2). However, the proportion suppressed among users of an NNRTI-based regimen was 
higher at all adherence levels compared to that among users of PI-based regimens (Figure 
3.4). The significant (P<0.05) difference in the minimum optimal adherence by regimen 
type persisted even after adjusting for the propensity for using NNRTIs and therefore we 
used stratified analyses to identify treatment-specific cutoffs. Users of PI-based regimens 
were less likely to suppress virus if <95% adherent compared to ≥95% adherent (e.g., 90-




the odds of HIV RNA suppression at adherence levels as low as 85% did not significantly 
differ compared to that with ≥95% adherence (OR: multi-pill users: 0.82 (0.64,1.04), 
single pill users: 0.88 (0.69, 1.11)). There were no differences in the proportions virally 
suppressed in NNRTI users with 90-94% adherence compared to ≥ 95% adherence (OR: 
1.10 (0.89, 1.36)). 
  Sensitivity analyses by varying the number of days on HAART inclusion 
criterion, and restricting to the first HAART regimen did not alter our results appreciably 
(Appendix Figure 3.3, Table 3.3).  
 
Discussion 
 In this population of HIV-infected treated persons seeking care at a Veterans 
Health Administration Center, adherence and viral load suppression improved between 
2001 and 2010, concomitant with use of newer HAART regimens. The proportion 
suppressed increased over time even among those with less than perfect adherence. More 
of those using NNRTI-based regimens had adherence ≥95%, and also a higher proportion 
suppressed at lower levels of adherence compared to those using other regimens.  
The utilization of newer HAART regimens in this study population is similar to 
that in other HIV-infected populations.
12
  Single-pill use began in 2006, and rose to 
almost 30% in 2010. The higher adherence observed with the use of single pill regimens 
conforms with studies contrasting the ease of use of single pill regimens and once-daily 
formulations with multi-dose regimens.
12-17
 and also with studies of medication use in the 
general population.
18
 Lower toxicity profiles may also have contributed to improved 




 In addition to being easier to administer, newer HAART formulations do not 
necessitate consistently high levels of adherence for viral load suppression as required by 
older HAART formulations.
2,16
  Second-generation drugs have enhanced 
pharmacokinetic profiles, lower toxicities and lower resistance rates, and lead to 
sustained viral load suppression.
2,19,20
  Our finding of a higher proportion sustaining viral 
load suppression in the latter era compared to the earlier era is consonant with the 
improved effectiveness of the newer drugs. Although a relatively new formulation, 
INSTI-based regimens had a lower proportion suppressed over time compared to other 
regimens. This may be attributed to the fact that this was the first-line regimen for less 
than 1% of the study population; their initial use was therefore predominantly as a 
salvage regimen for patients with failed prior regimens, who were as a consequence, 
more prone to virologic failure.   
Our data suggest that adherence levels lower than 95% may be sufficient for viral 
load suppression in populations using newer NNRTI formulations. Although based on 
relatively imprecise estimates (i.e., wide confidence intervals), 85-89% adherence on 
NNRTI-based regimens may be sufficient for viral load suppression; 82.2% of this group 
suppressed virus compared to 84.6% of those with ≥95% adherence. The inference of 
effective treatment with less than perfect adherence concurs with the literature suggesting 
that on the basis of pharmacy refill data, chronically ill patients using 80% of their 
medications are generally categorized as being adherent to their treatment.
21
 While being 
85% adherent to HAART may be sufficient for optimal virological outcomes in a 
population, we would like for this message to be interpreted with caution at the individual 




and comorbidities, may lead to sub-optimal adherence, resistance and treatment failure.
3
 
Providers must continue to encourage patients to achieve perfect adherence, but 




There were limitations in our study. We calculated adherence using pharmacy 
refill records, making the assumption that the medications were used as dispensed. While 
pharmacy refill records have the disadvantage that they may misrepresent adherence,
3
 
they are not associated with recall error and social-desirability bias as with other 
adherence measures like self-report and pill count.
3
 Although our findings are 
generalizable due to the large sample size with a widespread geographical distribution in 
the US, extrapolating our findings to women is limited since our population was 
predominantly male. The population had a higher CD4 count on average, and a higher 
proportion suppressed while on HAART than some other studies,
23
 and this may indicate 
different medication choices in this population. The generalizability of our findings is 
also limited due to the population being insured through the VA, indicating good access 
to care. The internal validity of our study is however boosted by this very fact since 98% 
of the participants do not refill their prescriptions outside of the VA.
24
 Resistance data 
were not available, and hence we do not know if PI-based regimens were used 
preferentially among patients with known resistance or known poor adherence.   
Despite the limitations, our study had several strengths. Over 20,000 HAART 
users were followed >10 years allowing us to reliably examine trends in adherence and 
viral load suppression, and determine the minimum adherence cutoff by HAART regimen 




based regimens have relatively better adherence and virological outcomes will enrich 
research on adherence in the current era by focusing attention to very low adherers. These 
data also serve as a guide for providers treating HIV-infected persons.  
An integral component of the treatment of HIV like other chronic illnesses is 
adherence. With newer HAART regimens, adherence is easier, and high adherence levels 
are not required for viral load suppression. Providers should not let concerns regarding 
barriers to adherence hinder the prescription of newer HAART regimens at early stages 
of the disease.
25
 A recent report by the Institute of Medicine on HIV treatment and 
quality of care states that “improving access to, and consistent use of medicines by HIV-
infected individuals would decrease their risk of transmitting the virus to others”.
26
 
Efforts must be made to maximize the prescription and use of single pill regimens. Future 
work should focus on the use of other approved single pill regimens and newer drugs 
now included as recommended regimens in more recent guidelines, and their use in 
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Adherence ≥ 95% 
(N person-years= 
33,555) 
Age, mean (SD) 45.7 (9.9) 51.9 (9.4) 53.6 (9.7) 
Black (%) 46.6 49.3 38.0 
Male (%) 98.0 97.9 98.3 
Smoking at baseline (%) 57.2 58.6 48.4 
Alcohol abuse (%)
δ





 13.4 13.1 8.1 
Depression status (%)
δ
 7.7 7.5 6.9 
CD4 count (cells/mm
3
), mean (SD) 422.1 (265.5) 480.6 (281.6) 521.0 (277.8) 
Geographical location (%)* 
  Northeast  
  Midwest  
  South  
















Year 2006 onwards 35.9 57.5 60.5 
Adherence at baseline, mean (SD)  87.6 (13.7) N/A N/A 
*Northeast: CT, ME, MA, NH, NJ, NY, PA, MD, DC, DE, RI, VT; Midwest: IL, IN, IA, KS, MI, MN,  MO, NE, ND, OH, 
 SD, WI; South: AL, AR, FL, GA, KY, LA, MS, NC, OK, SC, TN, TX, VA, WV; West: AK, AZ, CA, CO, HI, ID, MT, 
 NV, NM, OR, UT, WA, WY; 
δ 





Figure 3.1. Regimen use over time (2001-2010) 
N Person-years: 82,217 
 




















































Figure 3.2. Distribution of ≥95% adherence over time (2001-2010) 















































































2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
Calendar year 
                       Adherence 90-94%: N-person-years: 13,195 
                       Adherence 85-89%: N-person-years: 9,649 
                       Adherence 80-84%: N-person-years: 7,273 
                       Adherence 75-79%: N-person years: 5,632 
B 
(N person years: 48,662) 
(N person years: 38,174) 





Figure 3.4. Proportion suppressed by adherence category (2006-2010) 
N Person-years: 48,308 
 































Adherence percent category 
         Overall: N person-years: 48,308 
         NNRTI-based single pill: N person-years:8,789 
         NNRTI-based multi-pill: N person-years: 11,769 
         PI-based: N person-years: 24,283 




Figure 3.5. Odds ratios and 95% CI of HIV RNA suppression by adherence category (2006-2010) 
&
Adjusted for age, race alcohol abuse, major depression, drug abuse, geographical location, time since first HAART initiation 
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    NNRTI single pill 




Appendix Table 3.1. Change in adherence over time (2001-2010) 
N-person-years=82,217 
 
Model Time Unadjusted estimate Adjusted estimate 
Model 1: 
 
Per 1- year interval 0.07 (0.04, 0.10) 0.08 (0.04, 0.12) 
Model 2: 
 
Per 2- year interval 0.09 (0.03, 0.15) 0.13 (0.05, 0.20) 
Model 3: 2006-11 vs. 2001-05  0.18 (0.001, 0.36) 0.16 (-0.04, 0.36) 
&

















































0.26 (0.20, 0.34) 
0.36 (0.33, 0.39) 
0.39 (0.26, 0.58) 





0.51 (0.45, 0.58) 
0.66 (0.59, 0.74) 
0.77 (0.70, 0.85) 
0.94 (0.86, 1.03) 
0.55 (0.46, 0.67) 
0.69 (0.58, 0.82) 
0.79 (0.67, 0.92) 
1.05 (0.91, 1.21) 
*Excluding those with only one person-year; 
δ
Average treatment effect using propensity score included as 
covariate in model: PS: P(receiving an NNRTI-based regimen=1)| age, race, geographical location, time 
since first HAART initiation, lagged CD4, lagged HIV RNA, lagged drug abuse, lagged alcohol abuse, 


































Appendix Table 3.3. HIV RNA suppression by adherence category (odds ratios and 95% CI)* 
 






≥330 days  











0.72 (0.51, 1.01) 
1.02 (0.76, 1.37) 
0.96 (0.74, 1.25) 
1.18 (0.93, 1.49) 
0.62 (0.52, 0.74) 
0.77 (0.67, 0.88) 
0.87 (0.78, 0.98) 
0.95 (0.86, 1.06) 
0.65 (0.42, 1.03) 
0.95 (0.70, 1.30) 
1.02 (0.83, 1.24) 
1.04 (0.91, 1.19) 
*
Excluding those with only one person-year; 
#
Average treatment effect using propensity score included as covariate in model; 
 PS: P(receiving an NNRTI-based regimen=1)| age, race, geographical location, lagged CD4, lagged HIV RNA, lagged drug abuse, 




Appendix Figure 3.1 Distribution of ≥95% adherence by regimen type and 
daily dosing 































































Appendix Figure 3.2. Proportion of person-years with sustained viral load 
suppression (2001-2010)* 
N viral load tests=200,942 


























































NNRTI-based: N viral load tests: 84,722 
PI-based: N viral load tests: 103,387 




Appendix Figure 3.3. Sensitivity analysis: suppression according to adherence 
 

























Adherence percent category 
                ≥180 days: N person-years: 48,308 
                ≥270 days: N person-years: 35,483 
                ≥330 days: N person-years: 22,164 
 
A 
Adherence percent category 
          First HAART: N person-years:  6,937 






The Effect of Concomitant Medication Use on Adherence to Highly Active 














































The introduction of highly active antiretroviral therapy (HAART) over the past decade 
has led a decrease in AIDS-related morbidity and mortality, and an increase in the 
prevalence of chronic non-AIDS comorbidities and their subsequent treatment. We 
sought to determine the effect of pill burden due to use of concomitant medications for 
non-AIDS comorbidities in HIV-infected persons on adherence to HAART.  
Methods 
We used longitudinal data from two prospective cohort studies – the Multicenter AIDS 
Cohort Study (MACS) and the Veterans Aging Cohort Study virtual cohort (VACS VC) 
between March 2001 and December 2011, and October 2000 and September 2010 
respectively. In the MACS, adherence and the number of medications used for a chronic 
non-AIDS condition were calculated using self-reported measures (adherence over the 
previous 4 days and concomitant medication use since the prior visit). In the VACS, 
adherence and the total mean number of concomitant medications used for at least 90 
days in a given year were calculated using pharmacy refill records. Random-effects 
logistic regression models were used to determine the effect of the number of 
concomitant medications used on the minimum optimal adherence to HAART, and 
propensity score weighting was used to adjust for using more than the mean number of 
concomitant medications. 
Results 
A total of 1,194 MACS participants contributed 11,678 person-years between 2001 and 




2010. The number of concomitant medications used, and the proportion achieving 
minimum optimal adherence increased between 2006 and 2011, and this proportion was 
higher among persons older than 50 years, and persons with a higher VACS Risk Score.  
In the MACS, the odds of achieving minimum optimal adherence increased with an 
increase in the number of concomitant medications (≥4 vs. <2: 1.19 (0.75, 1.88)). In the 
VACS, the odds of achieving minimum optimal adherence increased with an increase in 
the number of concomitant medications for both NNRTI-based regimens (≥6 vs. <2: 1.84 
(1.57, 2.15)), and PI-based regimens (≥6 vs. <2: 1.97 (1.75, 2.23)).  
Conclusions 
Even though the use of concomitant medications for chronic non-AIDS comorbidities led 
to improved adherence, comprehensive treatment management, regular monitoring of 
medication use, and counseling of persons with complex treatment regimens are 














In the past decade, there has been a steep increase in the life expectancy of HIV-
infected persons which is now approaching that of uninfected persons.
1,2
  Owing to 
prolonged survival, inflammation associated with HIV, and toxicities associated with 
highly active antiretroviral therapy (HAART), HIV-infected persons now have a higher 
burden of comorbidities.
3
 The prevalence of non-AIDS comorbidities and the resultant 
use of medications co-administered with HAART have led to more complex treatment 
management in HIV-infected persons. 
Early in the HAART era, increased antiretroviral (ARV) regimen complexity and 
pill burden were some of main barriers to achieving optimal adherence to HAART.
4,5
  
Nevertheless, newer and second-generation formulations have enabled the overcoming of 
the barriers as they are easier to administer, e.g., single pill combination of 
Efavirenz/Tenofovir/Emtricitabine (EFV/TDF/FTC) and drugs such as Ritonavir-boosted 
Atazanivir (ATV/r), Elvitegravir (ETV), and Raltegravir (RTG) have improved 
pharmacokinetic and toxicity profiles. As a consequence, adherence to HAART has 
become easier, and they do not necessitate high levels of adherence for viral load 
suppression.  
The benefits of simplified, more safe and effective HAART regimens may 
however be complicated due to polypharmacy in HIV-infected persons.
6
 Polypharmacy, 
defined as the use of five or more medications,
7
 requires good access to care, including 
more health care visits, and also poses an increased risk for drug-drug interactions. Age is 
a strong predictor of polypharmacy,
8




concomitant medications compared to younger HIV-infected persons.
9
 The treatment of 
HIV and non-AIDS comorbidities is further complicated by the pathophysiology of aging 
in HIV-infected persons and illnesses such as chronic kidney disease and diabetes, which 
result in slow pharmacologic clearance and inconsistent drug absorption, eventually 
lowering drug effectiveness, and raising the risk for toxicity.
10
 In addition to the use of 
concomitant medications, the treatment of several chronic non-AIDS comorbidities such 
as diabetes and hypertension requires additional time-intensive self-care activities like 




However, older adults with HIV have better virological outcomes
10,11,12
 owing to 
better retention in care and adherence to HAART.
13
 Further, older persons are less likely 
to engage in risky behaviors that negatively impact adherence in persons with HIV and 
non-AIDS comorbidities such as substance abuse.
14,15
 For all persons on concomitant 
medications, improvement in the overall symptoms from comorbidities may further serve 
as a motivator for maintaining high levels of adherence to treatment over time.
14,16
 
There is a need to determine if improvement in HAART formulations is 
counterbalanced by increased treatment complexity due to concomitant non-AIDS 
medication use which is increasing in aging HIV-infected persons. We sought to 
determine the impact of using concomitant medications on adherence to HAART in a 







We used longitudinal data collected prospectively from participants in the 
Multicenter AIDS Cohort Study (MACS), and pharmacy fill/refill data, laboratory and 
clinical data from the Veteran Aging Cohort Study virtual cohort (VACS VC). 
 
Source populations 
The MACS is an ongoing prospective study of the natural history of HIV-1 
infection in men who have sex with men (MSM) in the United States.
17
 Eligible persons 
had to be sexually active, 18 years or older, and free an AIDS-defining illness, i.e., 
opportunistic infection or malignancy.
18
  Every six months, participants came to study 
visits which consisted of physical examinations, collection of blood for concomitant 
laboratory testing and storage, and collection of information on medical history, 
prescription medication use, demographics, and behaviors through standardized 
interviews. MACS study protocols were approved by institutional review boards at each 
study center, and informed consent was obtained from all participants.   
The VACS VC is a large ongoing, prospective clinical cohort of HIV-infected 
persons in care at Veterans Health Administration (VHA) centers nationwide.
19
 Details of 
the VACS VC have been previously described.
19
 We obtained laboratory and clinical 
data, and outpatient prescriptions for each patient by linking Immunology Case Registry, 







Definition of HAART 
 HAART was defined using the DHHS guidelines as ‘a combination ARV 
treatment regimen containing at least 3 ARV drugs - 2 nucleoside reverse-transcriptase 
inhibitor (NRTI) medications plus a protease inhibitor (PI), a non-nucleoside reverse-
transcriptase inhibitor (NNRTI), or an integrase strand transfer inhibitor (INSTI)’.
21
  In 
the MACS, the date of HAART initiation was set as the visit date of the first HAART 
report. In the VACS, the year of HAART initiation was set as the year of first HAART 
report. For each person-year, we used the regimen most frequently refilled to classify 
HAART as NNRTI-based, PI-based (including users of PIs, and both NNRTIs and PIs), 
INSTI-based, or 3 NRTI containing abacavir or tenofovir.  
 
Study population  
For this analysis, the MACS was restricted to HIV-positive men who reported 
HAART use at any time from March 1, 2001 to December 31, 2011. Only visits at which 
participants reported using HAART were included in the analysis. In the VACS, only 
person-years in which HAART was used for at least 180 days in the year were included. 
The analysis used longitudinal pharmacy refill data collected prospectively from HIV-
positive persons on HAART and followed in the VACS from October 1, 2000 through 





Outcomes and Exposures 
Adherence to HAART was defined using self-reported information collected at 
the study visits in the MACS.  The participant was asked about his actual use of each 
ARV medication over the four days prior to the study visit.  These responses were 
compared to the prescribed usage to determine adherence;  
 Sum of the number of times the patient took the drug over a 4-day period  * 100 
         Sum of the number of times they were expected to take the drug each day * 4 
Adherence to HAART was treated as a continuous variable, or dichotomized as ≥85% or 
less, which had been established as the minimum optimal adherence in the current era of 
treatment in the MACS.
22
  
In the VACS, we calculated adherence to HAART using the medication 
possession ratio defined by Steiner and colleagues
23
 which measures the duration of time 
the patient had the medications available, relative to the total number of days between 
refills. This was calculated for each person-year that contained at least one refill as 
follows: 
∑ 𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑑𝑎𝑦𝑠 𝑠𝑢𝑝𝑝𝑙𝑖𝑒𝑑 𝑤𝑖𝑡ℎ 𝑑𝑟𝑢𝑔 𝑖𝑛 𝑎 𝑦𝑒𝑎𝑟𝐴𝑅𝑉𝑠
∑ 𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑑𝑎𝑦𝑠 𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝑓𝑖𝑟𝑠𝑡 𝑎𝑛𝑑 𝑙𝑎𝑠𝑡 𝑟𝑒𝑓𝑖𝑙𝑙𝐴𝑅𝑉𝑠
∗ 100 
 
We excluded stockpilers (20.2% of study population), defined as person-years 
with a refill frequency exceeding the scheduled dosing interval by more than 5% since 
the Steiner algorithm was not validated in this subgroup.
20,24
 Adherence to HAART was 
treated as a continuous variable or dichotomized as ≥85% for person-years on NNRTI-




respectively, which were established as minimum optimal adherence cutoffs by HAART 
regimen type (Chapter 3).  
 Concomitant medication use in the MACS was calculated based on self-reported 
use of non-AIDS medications since the prior MACS visit. We classified drugs into 
pharmacological classes using the WHO Anatomical Therapeutic Chemical Classification 
(ATC) system,
25
 and further classified them into chronic use medications and short-term 
use medications. Our primary exposure variable was the number of medications used for 
chronic non-AIDS conditions. Appendix 4.1 lists the pharmacological classes used in our 
study populations. 
Concomitant medication use in the VACS was defined as the use of medications 
for non-AIDS conditions on a long-term basis.
26,27
 We determined receipt of all 
outpatient non-AIDS formulations dispensed through the VHA using pharmacy fill/refill 
data available through the PBM program.
19
  We defined concomitant medication use as 
using medications for at least 90 days in a year with a 30-day gap for fill-refill.
26
 
Medications were classified into pharmacological classes using the Department of 
Veterans Affairs (VA) drug classification system.
28
  We excluded pharmacy fill/refills 
classified as diagnostic supplies, emollients, eye washes and lubricants, soaps, shampoos 
and soap-free cleaners, mouthwashes, sun protectants and screens, irrigation solutions, 
ceruminolytics, deodorants and antiperspirants, and contact lens solutions from our 
analyses.
26
 We determined the total mean number of non-ARV long-term medications 







 ∑ (𝑀𝑒𝑑𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑟𝑒𝑓𝑖𝑙𝑙𝑒𝑑) ∗ (𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑑𝑎𝑦𝑠 𝑖𝑛 𝑟𝑒𝑓𝑖𝑙𝑙)𝑛𝑜𝑛−𝐴𝑅𝑉𝑠  
Number of days in the year when at least one medication for a non-AIDS condition was 
used 
Appendix 4.3 shows an example describing the calculation of the total mean number of 
non-ARV long-term medications received for each patient.   
 In the MACS, potential predictors of adherence and concomitant medication use 
were sociodemographic and behavioral characteristics reported for the 6 months prior to 
when adherence and concomitant medication use were ascertained. These included age, 
race, annual income (<$10,000 versus ≥$10,000), insurance status (private, public, none), 
current injection drug use, non-injection drug use (including cocaine, crystal 
methamphetamine, marijuana, heroin, poppers), current smoking, and moderate-heavy 
alcohol intake (3-4 drinks/day for more than once a month) compared to lower quantities. 
Treatment and disease characteristics included CD4 cell count (quantified using 
standardized flow cytometry)
17
 and HIV RNA levels (determined using the Roche 
Ultrasensitive RNA PCR assay (Hoffman-LaRoche, Nutley, NJ, U.S.A.) with a detection 
limit of 50 copies/ml),
17
 lagged to the previous visit, and number of ARV medications, 
history of AIDS (confirmed by medical record review) and non-AIDS comorbidities at 
each visit. The presence of diabetes, hypertension, dyslipidemia, liver disease, and kidney 
disease were determined using algorithms based on a combination of self-reported 
diagnosis and treatment, or based on clinical indices including laboratory test results for 
at least two consecutive visits. Depression was defined if treatment was self-reported or 




Depression Scale (CES-D) score greater than 16.
29
 Other chronic non-AIDS 
comorbidities were defined using ICD-9 diagnosis codes on medical records obtained to 
confirm self-reported information.  We also controlled for the type of HAART regimen 
(NNRTI-based, PI-based, INSTI-based, and single pill), and the short-term use of non-
ARV medications (only if participants reported using them over the past 4 days). 
 In the VACS, potential confounders of HAART adherence and concomitant 
medication use included sociodemographic, behavioral, disease and treatment 
characteristics. Fixed characteristics included race, smoking, and geographical location 
obtained at the first time seen after October 1, 2000 (baseline). Time-varying factors 
included the number of ARV medications used, and the HAART regimen type. Non-
AIDS comorbidities, AIDS status, and behaviors such as alcohol abuse and drug abuse 
were defined by ICD-9 diagnostic codes, and they required at least one inpatient or two 
outpatient diagnoses in a given year.
30,31
 We also adjusted for the VACS Index, which is 
a composite score of prognostic markers in treated HIV patients. This includes age, CD4 
cell count, HIV RNA and laboratory measurements of hemoglobin, aspartate and alanine 
transaminase (AST, ALT), platelets, creatinine, HCV status and composite markers of 





 We restricted the analysis to person-visits with non-missing covariates, 




concomitant medication use from 2001-2011, and compared the concomitant medication 
use by adherence levels, age (<50 years vs. ≥ 50 years), and HAART regimen type.  
 To examine the effects of concomitant medication use on adherence, we restricted 
the time to 2006 and onwards. We obtained adjusted probabilities for achieving the 
minimum optimal adherence using random-effects logistic regression models. In the 
MACS, using random-effects logistic regression models with minimum optimal 
adherence as a dichotomous outcome (≥85% and <85%), we examined the association 
between HAART adherence and the number of concomitant medications as a categorical 
variable (<2, 2-3, ≥4). Since characteristics informing prescribing patterns may affect 
adherence and the number of concomitant medications, we adjusted for possible 
confounding by indication using propensity scores to weight the model. The propensity 
score for using greater than the mean number of concomitant medications for a non-
AIDS condition was determined by logistic regression which included age, race, 
insurance status, alcohol use, smoking, non-injection drug use, injection drug use, 
depression, type of HAART, calendar year, viral load suppression and adherence lagged 
to previous visit. Weights were generated as the average treatment effect for the treated 
(ATT), trimmed at the 95
th
 percentile, and included in the repeated measures logistic 
regression model as a covariate. In the VACS, using random-effects logistic regression 
models adjusted for confounders, we examined the association between minimum 
optimal adherence and the number of concomitant medications (<2, 2-3, 4-5, ≥6) using 
separate models for HAART regimen type, since the minimum optimal adherence 




adjustment of confounders in the VACS since we had sufficient power to directly adjust 
for confounders in the primary regression model. 
Using multinomial logistic regression with HAART regimen type as a categorical 
outcome variable, we determined the effect of the number of concomitant medications on 
HAART regimen type, adjusted for confounders.  In order to examine the relationship 
between adherence and the number of concomitant medications used by the 
pharmacologic class of the concomitant medication, persons were classified as using 
medications from a particular pharmacologic class if they used at least one long-term 
medication from that class each year. In the MACS, the most frequently used classes of 
medications were determined, and we examined the association between adherence and 
the number of concomitant medications separately for each of these classes, both cross-
sectionally at the incident visit (defined as the first visit at which they reported using a 
drug from a given medication class), and longitudinally at visits following the incident 
visit. In the VACS, we used the same pharmacologic classes used in the MACS, since 
they represented some of the most commonly used medication classes in the literature.
9
 
To examine the association between concomitant medication use and HAART adherence 
at the incident visit in the cross-sectional dataset, we used a linear regression model with 
HAART adherence as a continuous outcome and the number of concomitant medications 
as a continuous exposure variable, adjusted for confounders. We examined the 
association between the minimum optimal HAART adherence and the number of 
concomitant medications using a random-effects logistic regression model among those 




All analyses were performed using SAS 9.2 (Cary, North Carolina, USA) and 
STATA 12.1 (College Station, Texas, USA).  A p-value threshold of 0.05 was used to 
define statistical significance. 
 
Results 
A total of 1,194 MACS participants contributed 11,678 person-years between 
2001 and 2011, and 21,708 VACS patients contributed 79,972 person-years between 
2001 and 2010. Characteristics of the MACS study population are shown in Table 4.1A 
and characteristics of the VACS study population are shown in Table 4.1B according to 
concomitant medication use.  
Unadjusted, in the MACS, using more than one concomitant medication (mean 
number of concomitant medications=2) was associated with older age, not being black, 
having higher incomes, smoking, but not using alcohol and recreational drugs. A majority 
of the persons using multiple concomitant medications had a higher CD4 cell count and a 
significantly higher proportion were virally suppressed compared to persons using less 
than 2 medications. Most persons used either a PI-based or NNRTI-based regimen, but 
the proportion using an INSTI-based regimen was significantly higher among those using 
multiple medications (9.0% vs. 2.6%, P<0.001).   
In the VACS, at baseline, the mean age was 45.7 years (standard deviation (SD): 
9.9), 98% were male, 46.6% were black, 57.2% were smokers, and almost 47% lived in 
the south. Unadjusted, the use of multiple concomitant medications was associated with 




more medications had a higher mean VACS Index, and used more PI-based and INSTI-
based regimens compared to those using less than the mean number of medications 
(mean=4). 
 
Concomitant medication use  
Figures 4.1 and 4.2 show the number of concomitant medications used by 
calendar time (Figure 4.1), and adherence level (Figure 4.2). In the MACS, the number of 
concomitant medications used increased slowly over time, with an increase in the upper 
quartile of the distribution between 2001 and 2005 (Figure 4.1A). As shown in Figure 
4.2A, persons with adherence greater than 85% used more concomitant medications 
compared to persons with adherence lower than 85% (Median (IQR): 1 (3) vs. 1 (2)). 
Similar to the MACS, the number of concomitant medications used increased slowly over 
time in the VACS (Figure 4.1B), and, it increased at higher levels of adherence as well 
(Figure 4.2B). Based on results from the logistic regression model used to obtain the 
propensity score in the MACS, significant predictors of using more than the mean 
number of concomitant medications in the current era of treatment were older age, white 
race, having insurance coverage, smoking, non-injection drug use, depression, using an 
INSTI-based regimen, and increasing levels of adherence and viral load suppression. 
In the VACS, using NNRTI-based regimens was associated with a lower number 
of concomitant medications compared to PI-based and INSTI-based regimen users 
(Appendix Figure 4.1). Figures 4.3A and 4.3B show results from the multinomial 




of concomitant medications. In the MACS, persons with more than 4 medications were 
1.5 times more likely to be on an INSTI-based regimen compared to an NNRTI-based 
regimen, and 83% less likely to be on a PI-based regimen compared to an NNRTI-based 
regimen. In the VACS, persons with more than 6 medications were 2.3 times more likely 
to be on an INSTI-based regimen compared to an NNRTI-based regimen, and almost as 
likely to be on a PI-based regimen compared to an NNRTI-based regimen (RR: 1.06). 
 
Class of concomitant medications 
Figures 4.4A and 4.4B show the type of concomitant medications used most 
frequently. In the MACS, lipid modifying agents (24.5%), CNS stimulants (15.5%), 
agents acting on the renin-angiotensin system (ACE inhibitors), (7.4%), drugs used in 
diabetes (5.9%) and beta-blockers (5.3%) were among the most frequently used classes 
between 2006 and 2011. In the VACS, lipid modifying agents (5.3%), antidepressants 
(5.2%), ACE inhibitors (3.7%), antirheumatic agents (3.4%) and non-opioid analgesics 
(3.2%) were the five most frequently used classes between 2006 and 2010. Further, in the 
MACS, the use of different classes of concomitant medications did not change over time, 
but they differed among age groups (Appendix Figure 4.3). Compared to persons younger 
than 50 years, older persons had a higher proportion using medications for cardiovascular 





Relationship between concomitant medication use and adherence 
 In both cohorts, the proportion achieving minimum optimal adherence increased 
with the number of concomitant medications, and was higher among persons older than 
50 years (Figures 4.5A and 4.5B), and persons with a higher VACS Index (Appendix 
Figure 4.2). This trend was consistent across all regimen types, although the proportion 
achieving minimum optimal adherence was higher among NNRTI-based regimen users. 
The adjusted probability of achieving minimum optimal adherence increased with 
use of more concomitant medications in the MACS (Figure 4.6A). The probability of 
achieving minimum optimal adherence was significantly higher among those using more 
than 3 concomitant medications compared to those using less than 2 concomitant 
medications (0.97 (0.96, 0.98) vs. 0.95 (0.94, 0.96)), respectively.  Random-effects 
logistic regression models weighted for the propensity score and adjusted for non-AIDS 
medications used for an acute condition taken in the past 4 days showed that the odds of 
achieving the minimum optimal adherence increased with an increase in the number of 
concomitant medications (≥2 vs. <2: 1.28 (0.95, 1.73)). The adjusted odds of achieving 
the minimum optimal adherence were attenuated compared to the unadjusted odds for the 
covariates of interest: age ≥50 (1.22(0.69, 1.73), race (white vs black: 1.54 (1.08, 2.20)), 
alcohol use (Yes vs. No (0.84 (0.62, 1.12)), smoking (Yes vs. No (0.91 (0.68, 1.22)) and 
depression (Yes vs. No (0.87 (0.64, 1.17)) (Table 4.2A).  
 In the VACS, the adjusted probability of achieving minimum optimal adherence 
increased with an increase in the number of concomitant medications for all HAART 




was significantly higher for users of NNRTI-based regimens compared to those using PI-
based regimens and INSTI-based regimens. Longitudinally, the odds of achieving 
minimum optimal adherence increased with an increase in the number of concomitant 
medications for both NNRTI-based regimens (≥6 vs. <2: 1.84 (1.57, 2.15)), and PI-based 
regimens (≥6 vs. <2: 1.97 (1.75, 2.23)) (Table 4.2B). The adjusted odds of achieving the 
minimum optimal adherence were almost unchanged compared to the unadjusted odds 
for the covariates of interest for both NNRTI-based and PI-based regimens.  
Figures 4.7A and 4.7B show the change in adherence after the use of a 
concomitant medication between 2001 and 2011. In both cohorts, there was an increase 
in adherence following the start of the medication if the baseline adherence was lower 
than 50%. At higher levels of baseline adherence, there was a decrease in adherence 
following the use of a concomitant medication. 
 
Incident use of concomitant medications from a particular class 
Figures 4.8A and 4.8B show results from five linear regression models with 
adherence percent as a continuous outcome, and concomitant medication use as a 
continuous exposure variable based on the use of at least one drug from each of the five 
pharmacologic classes. At the incident visit in the MACS, there was a decrease in 
adherence with an increase in the number of concomitant medications for persons using 
at least one ‘lipid modifying agent’, ‘drug used in diabetes’, ‘CNS stimulants’, or ‘beta-
blockers’, but there was a 1% increase in adherence with the use of every concomitant 




estimates were statistically significant. We examined similar classes in the VACS, but 
due to the higher prevalence, studied antidepressants instead of CNS Stimulants. There 
was a slight increase (<1%) in adherence with an increase in the number of concomitant 
medications for persons at the incident visit for each of the five medication classes, and 
the estimates were statistically significant (Figure 4.8B).  
 
Longitudinal use of concomitant medications from a particular class 
 Figure 4.9A shows results from five distinct repeated measures logistic regression 
models with minimum optimal adherence as a dichotomous outcome and concomitant 
medication use as a dichotomous exposure variable (≥mean number of medications vs. 
<mean number of medications) based on the use of at least one drug from each of the five 
pharmacologic classes in the MACS. The odds of achieving minimum optimal adherence 
was higher among those using more than the mean number of concomitant medications 
compared to those using less than the mean number of  concomitant medications for 
persons using at least one drug from the pharmacological classes: ‘lipid modifying 
agents’, ‘ACE inhibitors’, and ‘drugs used in diabetes’ but the results were not 
statistically significant.  
 Figure 4.9B shows results from five distinct repeated measures logistic regression 
models with minimum optimal adherence as a dichotomous outcome and concomitant 
medication use as a dichotomous exposure variable (≥mean number of medications vs. 
<mean number of medications) based on the use of at least one drug from each of the five 




adherence was higher among those using more than the mean number of concomitant 
medications compared to those using less than the mean number of concomitant 
medications for persons using at least one drug from pharmacological classes: 
‘antilipemics’, ‘ACE inhibitors’, ‘beta-blockers’, ‘antidepressants’ and ‘oral 




Polypharmacy and treatment complexity have been shown to impact adherence to 
HAART in HIV-infected persons.
4,5
 In our study populations of aging and treatment-
experienced HIV-infected MSM and veterans, the use of concomitant medications for 
chronic non-AIDS comorbidities has increased since 2001, in parallel with a rising 
burden of comorbidities.
7
 As observed in prior studies using these populations, adherence 
has improved over time, and the proportion achieving minimum optimal adherence has 
increased over time.  Longitudinally, the adherence to HAART was positively impacted 
with an increase in the number of concomitant medications used.  
 Independent predictors of minimum optimal adherence to HAART in both cohorts 
such as lower prevalence of alcohol use, smoking, and depression, are consistent with 
behaviors associated with optimal adherence in other studies.
33,34
 Similar to previous 
studies in HIV-infected populations and the general population, 
9,10,32
 variables associated 
with the prevalence of comorbidities such as age and VACS Index were strongly 




older individuals used more concomitant medications, and were more likely to achieve 
minimum optimal adherence compared to younger individuals. This finding was 
consistent with a recent meta-analysis on aging and adherence to HAART which showed 
that the aging population had better adherence to treatment, as they “may be more 
organized and experienced in their daily lives, or possibly more motivated after 
experiencing the initial devastating outcomes of the AIDS epidemic”.
13
 In contrast, 
persons with a lower VACS Index (i.e., younger and lower risk for morbidity and 
mortality),
32
 had a slightly higher proportion achieving minimum optimal adherence 
when adjusted for the number of concomitant medications. This could be attributed 
however to viral load suppression (an integral component of minimum optimal adherence 
and the VACS Index), which is associated with both a higher minimum optimal 
adherence and a lower VACS Index.  
 Provider decisions regarding the type of ARV or non-ARV medication used may 
be largely influenced by the potential for pharmacologic drug-drug interactions between 
ARV and non-ARV medications.
35
 The DHHS guidelines suggest regimen modification 
and dosing changes to prevent drug-drug interactions as a result of polypharmacy.
21
  Both 
NNRTI- and PI-based regimens are substrates and either inducers or inhibitors of 
cytochrome P-450 (CYP450),
 21,36
 an enzyme which is responsible for the majority 
(approximately 75%) of all drug metabolism.
37
 INSTI-based regimens do not impact 
CYP450 enzymes, and compared to other HAART regimens, they have an improved 
safety profile and fewer drug-drug interactions as a result of which, they are more likely 




INSTI-based regimens, PI-based regimens and NNRTI-based regimens had a 
significantly higher prevalence of drug-drug interactions (PI: prevalence ratio (PR): 4.96; 
NNRTI: PR: 2.48).
21,36
 Our finding that use of more concomitant medications was 
associated with the use of INSTI-based regimens compared to NNRTI-based regimens, is 
therefore consistent with recommended treatment guidelines and results from previous 
studies.
21
 In addition to safety and effectiveness considerations, PI-based regimens have a 
higher pill burden than other regimen types, and this could explain in part the preference 
of NNRTI-based regimens compared to PI-based regimens in persons using more 
concomitant medications in the MACS.  
The profile of concomitant medications used in these cohorts is similar to that 
reported in other HIV populations.
8,35
 In both cohorts, lipid modifying agents were the 
most commonly used class of medications, followed by ACE inhibitors, beta-blockers, 
and oral hypoglycemics. In the VACS, there was a high prevalence of antirheumatic 
agents and opioid analgesic use. This is comparable to the general veteran population, 
which has a 43% higher prevalence of chronic pain conditions compared to other 
American adults, and majority of the veteran population receives prescriptions for one or 
more analgesics.
38,39
 HIV-infected veterans in the VACS also had a higher prevalence of 
use of antidepressants compared to the MSM population in the MACS.  
The use of more concomitant medications was associated with significantly 
higher odds of achieving minimum optimal adherence in both cohorts. Furthermore, we 
found that in the current era of treatment, 84.2% and 77.0% were suppressed in the 






 Our finding of high adherence to HAART and sustained 
suppression despite high overall pill burden could be attributed to a better understanding 
of the effects of missed doses of HAART, and “linking disease symptoms to not taking 
medications”.
15
 In a recent study by Monroe et al, one of the emerging themes in the 
focus group discussions was the link between a good understanding of the health 
conditions and treatment adherence.
15
 Experiencing physical manifestations of their 
illnesses and the fear of high morbidity and mortality may have therefore acted as a 
motivator for better adherence to prescribed treatments for HIV.   
Albeit limited and conflicting, research findings also suggests that persons 
managing HIV and non-AIDS comorbidities tend to prioritize adherence to HAART over 
adherence to non-ARVs due to perceptions regarding the relative severity of HIV as an 
illness.
15,16
 Although we did not investigate adherence to concomitant medications in our 
study, this has been shown previously to be a predictor of adherence to HAART.
42
 Our 
restriction to the use of at least one medication from a given pharmacologic class was to 
determine if our finding of improved adherence with more concomitant medications 
varied by the type of concomitant medication used. The class of concomitant medication 
prescribed is innately linked to the comorbidity, the type of HAART regimen prescribed, 
and other patient characteristics such as age, substance use, other conditions, and results 
from clinical indices. Given that our findings were unchanged even after this restriction, 
we can conclude that the class of concomitant medication did not influence the 
association between adherence to HAART and number of concomitant medications for 




There were several limitations in our study. The use of concomitant medications 
was self-reported in the MACS, which may be associated with recall error. We were not 
able to further ascertain if the medications were taken as prescribed in the VACS. When 
examining the adjusted relationship between minimum optimal adherence and the 
number of concomitant medications, we observed an attenuation of the estimates in the 
MACS but only slight changes to our estimates in the VACS. This may be due to 
unaccounted bias arising from substance use (i.e., smoking, injection drug use, non-
injection drug use). There are significant differences in the prevalence of non-AIDS 
comorbidities in male and female HIV-infected persons.
43,44
 Given that our cohorts are 
largely male-dominated, the generalizability of our findings to women may therefore be 
limited. Another limitation may be the overrepresentation of persons with good access to 
care since the VACS population was insured through the VA PBM program,
45 
and in the 
MACS, a high proportion (93%) reported being insured. Further, as hypothesized by 
other studies, there may be potential selection bias due to the use of an older, treatment-
experienced population, with good access to care.
13
  
Our study had strengths as well. We used data from two long-standing 
observational cohort studies of HIV-infected persons in the United States, with a mean of 
7 years on HAART at the end of 2010, a mean age greater than 45 years, and using on 
average, more than 2 concomitant medications for a chronic non-AIDS condition.  
Although the MACS and the VACS consist of markedly different HIV-infected 
populations and use different measures of our primary exposure and outcome variables, it 




medication use were similar using both cohorts. We were able to determine that the 
improvement in HAART formulations was not counterbalanced by increased treatment 
complexity due to concomitant medication use for chronic non-AIDS comorbidities, and 
this finding will lead to a better understanding of the current treatment scenario. 
 
Conclusions 
 Notwithstanding the positive impact on adherence to HAART by increased non-
ARV pill burden, there is a need to invest resources into the management of non-AIDS 
comorbidities. Comprehensive counseling and medication therapy management must be 
provided for patients with multiple comorbidities to improve overall adherence to 
medications, minimize potential drug-drug interactions, and optimize overall treatment 
outcomes.
9
 While clinically significant drug-drug interactions and contraindications are 
well documented, continuous monitoring of the patients’ medication use patterns is 
necessary, given the increasing burden of polypharmacy.  In the light of increasing 
regimen complexity due to polypharmacy, future studies must attempt to tease apart 
associations between adherence to individual concomitant medications, and adherence to 
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Table 4.1A. Study population characteristics in the MACS (2001-2011) 











Age, mean (SD) 46.4 (8.4) 52.7 (8.0) <0.001 
Black 30.3 19.7 <0.001 
Alcohol use 15.1 11.8 <0.001 
Smoking  38.6 46.9 <0.001 
Injection drug use 1.8 1.8 1.0 
Non-injection recreational 
drug use 

















Income ≥$10,000  77.3 83.1 <0.001 
Viral load suppression  75.4 82.2 <0.001 
Non-AIDS Comorbidity 
(at least one)* 










  NNRTI-based 
  PI-based 
  INSTI-based 
















Baseline visit after 2001  53.9 34.3 <0.001 
*includes diagnosis of depression, diabetes, hypertension, dyslipidemia, liver disease, kidney disease, 






Table 4.1B. Study population characteristics in the VACS (2001-2010) 
 










N person-years:  
34,299 
Age, mean (SD) 45.7 (9.8) 44.1 (9.7) 47.8 (9.0) 
Black  46.6 45.2 43.6 
Male  98.0 98.1 98.0 
Smoking at baseline 57.2  -   - 
Alcohol abuse 
δ
 10.6 6.9 11.1 
Drug abuse
 δ
 13.5 9.2 14.3 
Depression status
δ
 7.8 5.1 11.0 
CD4 count (cells/mm
3
), mean (SD) 422.5 (266.3) 512.2 (273.8) 471.1 (291.7) 
Geographical location* 
  Northeast  
  Midwest  
























N person-years:  
34,299 
  West 16.3 15.4 17.5 
Viral load suppression 
VACS Index (complete) 


















  NNRTI-based 
  PI-based 
  INSTI-based 
















*Northeast: CT, ME, MA, NH, NJ, NY, PA, MD, DC, DE, RI, VT; Midwest: IL, IN, IA, KS, MI, MN,  MO, NE, 
ND, OH, SD, WI; South: AL, AR, FL, GA, KY, LA, MS, NC, OK, SC, TN, TX, VA, WV; West: AK, AZ, CA, CO, 
HI, ID, MT, NV, NM, OR, UT, WA, WY; 
δ 













Table 4.2A. Crude and adjusted associations between minimum optimal adherence 
and number of concomitant medications use and covariates in the MACS (2006-
2011) 
  
 Unadjusted OR (95% CI) 
of adherence ≥85% 
Adjusted OR (95% CI) 
of adherence ≥85%* 
Number of concomitant medications 
  2-3 
  ≥4 
 
1.47 (1.10, 1.97) 
1.68 (1.16, 2.44)  
 
1.24 (0.91, 1.68) 
1.10 (0.69, 1.73)         
Age ≥50 years (vs. <50 years) 1.72 (1.30, 2.29) 1.22 (0.69, 1.73) 
Race
^ 
  White 
  Other 
 
2.07 (1.44, 2.98) 
0.80 (0.51, 1.27) 
 
1.54 (1.08, 2.20) 
0.82 (0.53, 1.26) 
Alcohol use (Yes vs. No) 0.75 (0.56, 1.01) 0.84 (0.62, 1.12) 
Smoking (Yes vs. No) 0.68 (0.51, 0.93) 0.91 (0.68, 1.22) 
Depression status (Yes vs. No) 0.74 (0.57, 0.97) 0.87 (0.64, 1.17) 
Type of HAART
& 
  PI-based regimen 
  INSTI-based regimen 
 
0.72 (0.53, 0.98) 
1.37 (0.81, 2.30) 
 
0.76 (0.57, 1.01) 
1.28 (0.77, 2.15) 
*Odds ratios come from a repeated measures logistic regression model adjusted for number of concomitant 
medications, age, race, insurance status, alcohol use, smoking, non-injection drug use, injection drug use, depression, 
type of HAART, viral load suppression and adherence lagged to previous visit, non-chronic non-AIDS medications 
taken in the past 5 days, calendar year; ^Reference group for race is black; 
&





Table 4.2B. Crude and adjusted associations between minimum optimal adherence 
and number of concomitant medications and covariates by HAART regimen type in 
the VACS (2006-2010) 
 
NNRTI-based regimen (N person-years: 19,931) 
 
 Unadjusted OR (95% 
CI) of adherence ≥85% 
Adjusted OR (95% CI) 
of adherence ≥85%* 
Number of concomitant 
medications 
  2-3 
  4-5 
  ≥6 
 
 
0.97 (0.85, 1.10) 
1.46 (1.25, 1.70) 




1.50 (1.28, 1.75) 
1.84 (1.57, 2.15) 
Age ≥50 years (vs. <50 years) 1.70 (1.50, 1.92) 1.46 (1.29, 1.67) 
Race 
^ 
  White 
  Other 
 
2.81 (2.48, 3.19) 
1.73 (1.44, 2.07) 
 
2.38 (2.10, 2.70) 
1.58 (1.32, 1.89) 
Alcohol abuse (Yes vs. No) 0.55 (0.46, 0.65) 0.74 (0.61, 0.89) 
Drug abuse (Yes vs. No) 0.46 (0.39, 0.54) 0.60 (0.51, 0.72) 
Depression status (Yes vs. No) 0.88 (0.73, 1.06) 0.88 (0.72, 1.06) 
VACS Risk Score greater than 
mean (vs. less than mean) 
0.87 (0.79, 0.97) 0.76 (0.68, 0.85) 
*Odds ratios come from a repeated measures logistic regression model adjusted for number of concomitant 
medications,  age, race, alcohol abuse, drug abuse, major depression diagnosis,  adherence and viral load 
suppression lagged to  previous visit, calendar year, presence of a non-AIDS comorbidity, AIDS diagnosis, 





PI-based regimens (N person-years: 23,647) 
 
 Unadjusted OR (95% 
CI) of adherence ≥95% 
Adjusted OR (95% CI) 
of adherence ≥95%* 
Number of concomitant 
medications 
  2-3 
  4-5 
  ≥6 
 
 
1.02 (0.92, 1.13) 
1.30 (1.15, 1.47) 
1.89 (1.68, 2.13) 
 
 
1.08 (0.97, 1.20) 
1.37 (1.22, 1.55) 
1.97 (1.75, 2.23) 
Age ≥50 years (vs. <50 years) 1.71 (1.55, 1.88) 1.59 (1.44, 1.76) 
Race 
^ 
  White 
  Other 
 
1.99 (1.81, 2.19) 
1.52 (1.31, 1.75) 
 
1.76 (1.60, 1.94) 
1.40 (1.21, 1.61) 
Alcohol abuse (Yes vs. No) 0.68 (0.59, 0.77) 0.82 (0.70, 0.95) 
Drug abuse (Yes vs. No) 0.68 (0.60, 0.76) 0.87 (0.76, 0.99) 
Depression status (Yes vs. No) 0.90 (0.78, 1.04) 0.87 (0.75, 1.07) 
VACS Risk Score greater than 
mean (vs. less than mean) 
0.87 (0.81, 0.95) 0.78 (0.72, 0.85) 
*Odds ratios come from a repeated measures logistic regression model adjusted for number of concomitant 
medications,  age, race, alcohol abuse, drug abuse, major depression diagnosis,  adherence and viral load 
suppression lagged  to previous visit, calendar year, presence of a non-AIDS comorbidity, AIDS diagnosis, 
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Figure 4.2B.  Concomitant medication use by HAART adherence category in the 
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Figure 4.3A.  Association between HAART regimen type and number of 
concomitant medications in the MACS (2006-2011) 
Relative risk ratio estimates come from a multinomial regression model with HAART regimen type as 
outcome (NNRTI-based regimen as reference) and the number of concomitant medications as the main 
exposure variable (less than 2 medications as reference category), adjusted for age, race, smoking, alcohol 
use, non-injection drug use, minimum optimal adherence, baseline visit (before or after 2001), and viral 
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Figure 4.3B.  Association between HAART regimen type and number of 
concomitant medications in the VACS (2006-2010) 
 
 
Relative risk ratio estimates come from a multinomial regression model with HAART regimen type as 
outcome (NNRTI-based regimen as reference) and number of concomitant medications as the main 
exposure variable (less than 2 medications as reference category), adjusted for age, race, alcohol abuse, 
drug abuse, major depression diagnosis, adherence lagged to previous year, geographical location, VACS 
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Figure 4.4A. Use of concomitant medications for chronic non-AIDS conditions 
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Figure 4.4B. Use of concomitant medications for chronic non-AIDS conditions 
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Figure 4.5A. Minimum optimal adherence according to concomitant medication use 
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Figure 4.5B. Minimum optimal adherence according to concomitant medication use 
by age in the VACS (2006-2010) 
  
 
*Minimum optimal adherence for NNRTI-based regimens: ≥85%; Minimum optimal adherence for PI-
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Figure 4.6A. Adjusted probability of minimum optimal adherence by concomitant 
medication use over time in the MACS (2006-2011) 
 
*Adjusted probability comes from a repeated measures logistic regression model adjusted for age, race, 
insurance status, alcohol use, smoking, non-injection drug use, injection drug use, depression, type of 















































Figure 4.6B. Adjusted probability of minimum optimal adherence by concomitant 
medication use over time (2006-2010) 
 
*Adjusted probability comes from a repeated measures logistic regression model adjusted for age, race, 
alcohol abuse, drug abuse, major depression diagnosis, adherence and viral load suppression lagged to 















































Figure 4.7A. Change in adherence before incident use of a concomitant medication 
and adherence at incident visit in the MACS (2001-2011)  
N= 120 
 
                                    
 
*X-axis: adherence percent at the visit before the incident visit; Y-axis: difference in adherence 
 between the incident visit and the previous visit; **only persons at the visit before the incident visit; 
excluding persons with only one visit or a visit interval greater than 1 year and excluding persons with 
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Figure 4.7B. Change in adherence before incident use of a concomitant medication 
and adherence at incident visit in the VACS (2001-2010)      
 N=11,177       
 
           
 
*X-axis: adherence percent at the visit before the incident visit; Y-axis: difference in adherence 
 between the incident visit and the previous visit; **only persons at the visit before the incident visit; 
excluding persons with only one visit or a visit interval greater than 1 year and excluding persons with 
adherence at the visit before the incident visit not equal to 0 or 100% 
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Figure 4.8A. Adherence according to number of medications used in populations 
representing incident use among those using at least one drug from medication 
classes in the MACS (2001-2011) 
 
Estimates come from a linear regression models with adherence percent as outcome and concomitant 
medications as a continuous exposure adjusted for age, race, alcohol use, smoking, income, non-injection 
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Figure 4.8B. Adherence according to number of medications used in populations 
representing incident use among those using at least one drug from medication 
classes in the VACS (2001-2010) 
 
 
Estimates come from a linear regression model with adherence percent as outcome and concomitant 
medications as a continuous exposure adjusted for age, race, alcohol abuse, drug abuse, major depression 
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Figure 4.9A Odds of minimum optimal adherence according to number of 
medications used in populations among those using at least one drug from 
medication classes in the MACS (2001-2011)  
Odds ratios and 95% CI come from repeated measures logistic regression models with the minimum 
optimal adherence cutoff of 85% as the outcome and exposure dichotomized at mean concomitant 
medication use, adjusted for age, alcohol use, smoking, non-injection recreational drug use, income, type of 








0 0.5 1 1.5 2 2.5 3 3.5 4
Odds ratio and 95% CI 
 x   CNS Stimulants (N person-years=2,564) 
      Lipid modifying agents (N person-years=3,352) 
      Agents acting on renin-angiotensin system (N person-years=1,290) 
      Beta-blocking agents (N person-years=874) 




Figure 4.9B. Odds of minimum optimal adherence according to number of 
medications used in populations among those using at least one drug from 
medication classes in the VACS (2001-2010)  
 
Odds ratios and 95% CI come from repeated measures logistic regression models with the minimum 
optimal adherence cutoff as the outcome and exposure dichotomized at mean concomitant medication use, 
adjusted for age, race, alcohol abuse, drug abuse, major depression diagnosis, type of HAART regimen, 
VACS Risk Score; minimum optimal cutoff depends on the type of HAART regimen used: NNRTI: ≥85%, 














0.8 1 1.2 1.4 1.6 1.8 2 2.2 2.4
Odds ratio and 95% CI 
     Antidepressants (N person-years: 16,271)  
      Antilipemic agents (N person-years: 18,102) 
      ACE Inhibitors (N person-years: 11,713) 
   X Beta-blockers (N person-years: 9,431)  
































































NNRTI-based                PI-based                    INSTI-based          3 NRTI 




























Appendix Figure 4.2. Adherence according to number of concomitant medications 
used by mean VACS risk score in the VACS (2006-2010) 
*Minimum optimal adherence for NNRTI-based regimens: ≥85%; Minimum optimal adherence for PI-
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Appendix Figure 4.3. Use of concomitant medications for chronic non-AIDS conditions (2006-2011) by 
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Appendix 4.1.  List of pharmacological classes used in the MACS according to WHO ATC  
Main Group Therapeutic group Pharmacologic group 
Alimentary tract and metabolism   
 Bile and liver therapy  
 Drugs used in diabetes 
 
1. Insulins and analogues 
2. Blood glucose lowering drugs, 
excluding insulins 
3. Other drugs used in diabetes 
 
Blood and blood forming organs   
 Antithrombotic agents  
 Antihemorrhagics  
 Antianemic preparations  
 Other hematological agents  
 
Cardiovascular system   
 
 
Cardiac therapy A. Cardiac glycosides 
B. Antiarrhythmics, class I and 
III 
C. Cardiac stimulants excluding 
cardiac glycosides 
D. Vasodilators used in cardiac 
diseases 
E. Other cardiac preparations 
 
 
Antihypertensives A. Antiadrenergic agents, 
centrally acting 
B. Antiadrenergic agents, 
ganglion-blocking 
C. Antiadrenergic agents, 
peripherally acting 
D. Arteriolar smooth muscle, 





Main Group Therapeutic group Pharmacologic group 
L. Antihypertensives and 
diuretics in combination 




A. Low-ceiling diuretics, 
thiazides 
B. Low-ceiling diuretics, 
excluding thiazides 
C. High-ceiling diuretics 
D. Potassium-sparing agents 
E. Diuretics and potassium-
sparing agents in combination 
X. Other diuretics 
 Peripheral vasodilators  
 Vasoprotectives 
 
B. Antivaricose therapy 
C. Capillary stabilizing agents 
 
 
Beta blocking agents A. Beta blocking agents 
B. Beta blocking agents and 
thiazides 
C. Beta blocking agents and other 
diuretics 
D. Beta blocking agents, 
thiazides and other diuretics 
E. Beta blocking agents and 
vasodilators 




Calcium channel blockers C.Selective calcium channel 
blockers with mainly vascular 
effects 
D. Selective calcium channel 




Main Group Therapeutic group Pharmacologic group 
effects 
E. Non-selective calcium channel 
blockers 




Agents acting on the renin-angiotensin 
system 
A. ACE inhibitors, plain 
B. ACE inhibitors, combinations 
C. Angiotensin II antagonists, 
plain 
D. Angiotensin II antagonists, 
combinations 





Lipid modifying agents A.Plain 
1. HMG CoA 
2. Fibrates 
3. Bile acid sequestrants 
4. Nicotinic acid derivatives 
5. Other lipid modifying agents 
B.Combinations 
1. HMG CoA reductase inhibitors 
in combination with other lipid 
modifying agents 
2. HMG CoA reductase 
inhibitors, other combinations 
   
Systemic hormonal prep   
 Pituitary and hypothalamic hormones 
and analogues 
 
 Corticosteroids for systemic use  
 Thyroid therapy  




Main Group Therapeutic group Pharmacologic group 
 Calcium homeostasis  
 
Antiinfectives for systemic use   
 Antimycobacterials  





 Antineoplastic agents  
 Endocrine therapy  
 Immunostimulants  
 Immunosuppressants  
 
Musculo-skeletal system    
 Antiinflammatory and antirheumatic 
products 
 
 Muscle relaxants  
 Antigout preparations  
 Drugs for treatment of bone disease  
 
Nervous system   
 Antiepileptics  










C. Psycholeptics and 
psychoanaleptics 
D. Anti-dementia drugs 




Appendix 4.2.  List of pharmacological classes used in the VACS according to VA Class Index 
VA class  
am110 penicillin-g related penicillins                       cn101 opioid analgesics                                   
am111 penicillins,amino derivatives                         cn102 opioid antagonist analgesics                          
am112 penicillinase-resistant penicillins                    cn103 non-opioid analgesics                               
am115 cephalosporin 1st generation                           cn105 antimigraine agents                                   
am116 cephalosporin 2nd generation                            cn204 local anesthetics,injection                             
am117 cephalosporin 3rd generation                            cn300 sedatives/hypontics                                     
am118 cephalosporin 4th generation                             cn301 barbituric acid derivative sedatives/hypnotics        
am119 beta-lactams antimicrobials,other                        cn302 benzodiazepine derivative sedatives/hypnotics        
am200 erythromycins/macrolides                             cn309 sedatives/hypnotics,other                            
am250 tetracyclines                                         cn400 anticonvulsants                                     
am300 aminoglycosides                                        cn500 antiparkinson agents                                  
am350 lincomycins                                           cn550 antivertigo agents                                    
am500 antituberculars                                       cn601 tricyclic antidepressants                            
am550 methenamine salts antimicrobials                       cn602 monamine oxidase inhibitor antidepressants             
am600 nitrofurans antimicrobials                             cn609 antidepressants,other                               
am650 sulfonamide/related antimicrobials                   cn701 phenothiazine/related antipsychotics                 
am700 antifungals                                          cn709 antipsychotics,other                                 
am800 antivirals                                          cn750 lithium salts                                        
am900 anti-infectives,other                                cn801 amphetamines                                           
am119 beta-lactams antimicrobials,other                        cn802 amphetamine like stimulants                           
am200 erythromycins/macrolides                             cn809 cns stimulants,other                                  




VA class  
am300 aminoglycosides                                        cv050 digitalis glycosides                                 
am350 lincomycins                                           cv100 beta blockers/related                               
am500 antituberculars                                       cv150 alpha blockers/related                               
am550 methenamine salts antimicrobials                       cv200 calcium channel blockers                            
am600 nitrofurans antimicrobials                             cv250 antianginals                                         
am650 sulfonamide/related antimicrobials                   cv300 antiarrhythmics                                       
am700 antifungals                                          cv350 antilipemic agents                                  
am800 antivirals                                          cv400 antihypertensive combinations                        
am900 anti-infectives,other                                cv490 antihypertensives,other                              
hs051 glucocorticoids                                      cv500 peripheral vasodilators                                
hs052 mineralocorticoids                                     cv701 thiazides/related diuretics                         
hs100 androgens/anabolics                                  cv702 loop diuretics                                       
hs200 contraceptives,systemic                               cv703 carbonic anhydrase inhibitor diuretics                 
hs300 estrogens                                             cv704 potassium sparing/combinations diuretics             
hs400 gonadotropins                                           cv709 diuretics,other                                         
hs500 blood glucose regulation agents                         cv800 ace inhibitors                                      
hs501 insulin                                              cv805 angiotensin ii inhibitor                             
hs502 oral hypoglycemic agents,oral                       cv806 direct renin inhibitor                                   
hs503 antihypoglycemics                                           cv900 cardiovascular agents,other                           
hs600 parathyroid                                             re101 anti-inflammatories,inhalation                       
hs701 anterior pituitary                                      re102 bronchodilators,sympathomimetic,inhalation           
hs702 posterior pituitary                                    re103 bronchodilators,sympathomimetic,oral                   




VA class  
hs851 thyroid supplements                                  re105 bronchodilators,anticholinergic                      
hs852 antithyroid agents                                     re108 antiasthma,antileukotrienes                           
hs875 prostaglandins                                        re109 antiasthma,other                                     
hs900 hormones/synthetics/modifiers,other                  re200 decongestants,systemic                                
 re301 opioid-containing antitussives/expectorants           
 re302 non-opioid-containing antitussives/expectorants      
 re400 mucolytics                                              
 re501 antihistamine/decongestant                            
 re503 antihistamine/decongestant/expectorant                  
 re507 antihistamine/antitussive                                
 re513 decongestant/antitussive/expectorant                     
 re516 decongestant/expectorant                               
 re599 cold remedies,other                                    




Appendix 4.3. Example showing the calculation of the total mean number of non-ART long-term medications received 
for each patient in the VACS 
 ∑ (𝑀𝑒𝑑𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑟𝑒𝑓𝑖𝑙𝑙𝑒𝑑) ∗ (𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑑𝑎𝑦𝑠 𝑖𝑛 𝑟𝑒𝑓𝑖𝑙𝑙)𝑛𝑜𝑛−𝐴𝑅𝑉𝑠  
Number of days in the year when at least one medication for a non-AIDS condition was used 
Consider patient X fills her prescriptions between October 1, 2005 and September 30, 2006.  She fills prescriptions for Lipitor 
20mg on October 5, 2005 for 90 days, returns on January 10, 2006 to refill the prescription for 90 days, on April 14, 2006 to 
refill for 90 days, and on July 15, 2006 to refill for 90 days. She also refills a prescription for Prandin 1mg on December 2, 
2005 for 90 days, returns on March 5, 2006 to refill for 90 days, and on June 15, 2006 to refill for 90 days.  The total mean 
number of non-ART long-term medications can be calculated as follows:  




Days without any 
medication 
Lipitor 20mg Oct 1, 2005 to 
Jan 3, 2006 
90   
 Jan 10, 2006 to 
Apr 10, 2006 




















Apr 14, 2006 to 
Jul 13, 2006 
Jul 15, 2006 to  
Oct 13, 2006 
 
Dec 2, 2005 to  
Mar 2, 2006 
Mar 5, 2006 to 
May 31, 2006 
Jun 15, 2006 to 

















Oct 1 to Dec 2= 62 
 
Mar 3 to Mar 4=2 
 













Total days without any 
medication =0 
 
Since Lipitor 20mg and Prandin 1mg were refilled for a total of 7 times that year, numerator=90*7= 630 
Since the number of days without any medication=0, the denominator (number of days when at least one drug was used) = 364 
Therefore, the total mean number of non-ART long-term medications received for patient X between 2005 and 2006 = 630/ 












Summary of findings 
This dissertation generates essential knowledge regarding adherence to HAART 
in the current era of treatment.  We determined the minimum needed adherence level to 
HAART for viral load suppression in two distinct risk groups of HIV-infected persons in 
the US – MSM and IDU. Further, we evaluated whether this minimum optimal adherence 
cutoff was different by HAART regimen type using a large observational cohort of HIV-
infected veterans presenting at Veterans Health Administration centers nationwide. 
Notwithstanding the simplification and enhancement in safety and efficacy of HAART 
formulations, and the associated improvement in adherence and viral load suppression 
over time, HIV-infected persons now use concomitant medications for chronic non-AIDS 
conditions, which has led to increased treatment complexity. We examined whether the 
increased treatment complexity was a barrier in adhering to HAART regimens in the 
current era of treatment.  
 As shown in Chapter 2, we evaluated the minimum optimal adherence to HAART 
using self-reported adherence, and data in laboratory tests and physical examinations 
from two longitudinal interval cohort studies of HIV-infected persons in the US - the 
MACS and the ALIVE. We found that the proportion reporting high levels of adherence 
(≥95%) increased over time (ptrend<0.001) in both cohorts. Even among those reporting 
less than 95% adherence, the proportion with suppressed viral load increased over time 
(ptrend<0.001) in both cohorts. Overall, the most commonly used HAART regimen 
between 2001 and 2011 was PI-based in both cohorts. In the MACS, levels of adherence 
as low as 80% were sufficient for viral load suppression, with over 80% of the population 




at adherence levels ≥ 95% adherence (OR: 1.43 (0.61, 3.33)).  In the ALIVE, less than 
80% were suppressed even at near perfect levels of adherence, and the odds of 
suppression at adherence <95% was lower than that at adherence ≥95%. We therefore did 
not observe a minimum optimal adherence cutoff lower than 95% in the ALIVE.  
However, since we used two cohorts for analysis, we were able to identify several targets 
for adherence interventions, particularly in the IDU population based on a comparison of 
the results with the MSM group such as substance use, the use of older HAART 
regimens, and gaps in treatment and factors related to gaps in treatment such as 
incarceration, homelessness and low income.  
 As shown in Chapter 3, we determined the minimum optimal adherence to 
specific HAART regimens using pharmacy refill data, clinical and laboratory records 
from the VACS virtual cohort. Similar to our findings in the MACS and the ALIVE, the 
proportion reporting high levels of adherence, and the proportion suppressed even among 
those with <95% adherence increased over time. At the end of 2010, almost 30% of the 
study population used NNRTI-based single pill regimens, and 11% used INSTI-based 
regimens. Compared to PI-based and INSTI-based regimens, the use of NNRTI-based 
regimens was associated with a higher proportion achieving HIV RNA suppression with 
near-perfect levels of adherence. Among NNRTI users, the odds of HIV RNA 
suppression did not significantly differ compared to that with ≥95% adherence at 
adherence levels lower than 95% (OR: 85-89% adherence: multi-pill users: 0.82 
(0.64,1.04) and 90-94% adherence: 1.10 (0.89, 1.36)). Conversely, we found that users of 
PI-based regimens were less likely to suppress virus at adherence levels lower than 95% 




findings from the MACS, shows that newer formulations i.e., NNRTI-based regimens are 
more forgiving in terms of effectiveness at lower levels of adherence than what was 
needed for earlier HAART formulations.   
 In Chapter 4, we showed results on the effect of increased treatment complexity 
due to chronic use of concomitant medications for non-AIDS conditions on adherence to 
HAART using data from the MACS and the VACS.  The use of concomitant medications 
increased over time, and persons older than 50 years were more likely to use concomitant 
medications and achieve minimum optimal adherence in both cohorts.  The use of more 
concomitant medications was associated with the use of INSTI-based regimens compared 
to other regimens. The most commonly used classes of non-AIDS medications in both 
cohorts were lipid modifying agents, beta-blockers, ACE inhibitors, and oral 
hypoglycemics. Longitudinally, the odds of achieving minimum optimal adherence  
increased with an increase in the number of concomitant medications in the MACS (≥4 
vs. <2: 1.19 (0.75, 1.88)) and the VACS for both NNRTI-based regimens (≥6 vs. <2: 1.84 
(1.57, 2.15)), and PI-based regimens (≥6 vs. <2: 1.97 (1.75, 2.23)). The results did not 
change even upon restricting the population to the use of specific pharmacologic classes 
of concomitant medications. This study sheds light on the need for continued emphasis 
on treatment management and adherence counseling in persons being treated for HIV and 
non-AIDS comorbidities, despite the improvements in HAART formulations, and the 







Public health implications 
 This dissertation confirmed a lower cutoff of optimal adherence, and showed that 
polypharmacy did not negatively impact adherence to HAART in the current era of 
treatment. Prescribing HAART to HIV-infected persons early in the infection has been 
shown to have numerous benefits such as decreased progression of the disease to AIDS, 
and a lower probability of transmission of the disease to persons at risk.
1,2
 Benefits of 
early HAART initiation even in persons with suboptimal adherence, have been found to 
outweigh the risks associated with non-adherence (i.e., long-term toxicity, drug 
resistance, and regimen changes).
3
  
 The levels of adherence needed for viral load suppression in different HIV-
infected risk groups will enable providers of HIV care to better position their decisions 
regarding HAART use early in the course of infection. Our findings regarding poor 
retention to treatment, more barriers to adherence and lack of sustained virologic 
suppression in HIV-infected IDUs are consistent with previous studies looking at 
treatment-experienced IDU populations.
4,5,6
 Early initiation of treatment with newer and 
improved regimens despite the barriers to adherence will lead to better treatment 
outcomes in the long-term. Providers can redistribute time and resources to persons with 
specific barriers to adherence, and provide comprehensive adherence-improvement 
interventions, adherence monitoring, and counseling sessions, especially to persons with 
mental illnesses, using non-prescription drugs and to IDUs. There is a need to focus on 
retaining these persons in care since we found a significant association between gaps in 




 The first-line regimens in ART-naïve persons have been discussed in Chapter 1. 
Our analysis was adjusted for factors that influenced the prescription of specific HAART 
regimens, and we observed that NNRTI-based regimens have better adherence overall, 
which could be attributed to ease of administration, and a lower minimum optimal cutoff 
of adherence compared to PI-based regimens and INSTI-based regimens. HIV-infected 
persons with poor access to care and barriers to adherence should be prescribed single pill 
regimens or INSTI-based regimens owing to ease of administration.  
 Even though polypharmacy did not have a negative impact on adherence to 
HAART, management of the medications taken by the patient at every visit is essential to 
prevent potential drug-drug interactions, and ensure medication safety. A recent study by 
Gleason et al
7
 on polypharmacy in the older HIV-infected population suggested the need 
for “a thorough review of the medications”, and “an annual medication reconciliation and 
a medical review at every visit”. Some potential considerations during the review should 
include a check of whether the medications are on the list of inappropriate medications, 
and if necessary make appropriate dose changes, or change the drug used. Patients should 
be counseled and educated about all their comorbidities and their treatment. Studies have 
shown that knowledge of a disease and the consequence of not taking a medication 
regularly can impact adherence to medications.
8
 While this partly explains our findings 
regarding the relationship between HAART adherence and polypharmacy, it is important 
for adherence to all their medications to be evaluated as part of the review. Although 
potential drug-drug interactions between ARV and non-ARV medications are well-




monitoring of medications will ensure a strong evidence base for the management of 
treatment in HIV-infected persons in the current era of treatment.  
 
Future directions 
 Although the findings from this dissertation will serve to guide providers in 
decision-making, future studies need to corroborate this work with studies involving 
other important HIV risk groups such as women.  Given that women have lower rates of 
adherence,
9
 and higher rates of virologic failure compared to men, the minimum optimal 
adherence cutoff in women may be different from that observed in other risk groups. We 
did not find significant differences in adherence and treatment outcomes by gender in our 
IDU population, and it may be worth focusing on women with lower rates of substance 
use.  
 A significant risk factor of poor adherence and virologic failure is gaps in 
treatment. Future work should evaluate the impact of interventions to improve retention 
in care, and if they changed the minimum optimal adherence to HAART in these 
individuals. Further, if persons with poor access to and retention in care were prescribed 
newer HAART medications, the impact of using these drugs on the minimum optimal 
adherence to HAART needs to be examined.  
 Switching regimens as a result of drug resistance and virologic failure is a 
relatively common occurrence in treatment-experienced HIV-infected persons.
10
  Drug 
resistance is likely to impact the minimum optimal adherence to HAART, since 
virological suppression may not happen despite high levels of adherence. We were not 




resistance as a potential confounder in the analysis. In Chapter 3, although we did 
sensitivity analysis by restricting the study population in the VACS to the first regimen 
used, it will be interesting to observe the change in the minimum optimal adherence 
threshold within a year after regimen changes. It will also be interesting to determine how 
adherence to specific components of the HAART regimen modify the minimum optimal 
adherence to HAART. 
The minimum optimal adherence should be determined using other measures of 
adherence like MEMS cap. This form of adherence measurement although not the gold 
standard, has been proven more accurate than self-report and pharmacy refill records in 
measuring adherence in different populations.
11
 Although we did not determine any 
significant differences in the minimum optimal adherence between self-reported 
adherence and adherence using pharmacy refill records, it will be interesting to evaluate 
changes in the minimum optimal adherence cutoff on using a relatively more accurate 
measure.  
 In the context of concomitant medication use, the impact of adherence to 
concomitant medications on adherence to HAART should be examined. In trying to 
obtain a holistic view of treatment adherence in HIV-infected persons, providers can use 
this knowledge to identify points of intervention and areas that will need counseling. A 
thorough documentation of adherence to different concomitant medications and their 
relationship with adherence to HAART will be a useful resource for providers. More 
qualitative research such as focus groups are needed to learn about patient-related 
behaviors that motivate adherence to non-ARV medications. Although similar work has 
been done by Monroe et al
8




perception of different chronic non-AIDS comorbidities by patients, and how that 
motivated them to adhere to medications will help remedy the gap in understanding how 




With several new HAART formulations in the pipeline, research needs to 
constantly address previously studied issues in the light of improved formulations, as 
well as innovate and solve new problems associated with the treatment of HIV to fill gaps 
in the literature. The ultimate goal is to keep up with developments in HAART 
formulations, and relentlessly replenish the knowledge base regarding adherence to 
HAART and other treatment outcomes in the changing treatment scenario. This will 
guide providers of HIV care and policy-makers alike, in providing effective and safe 
treatment to HIV-infected persons, and maximizing and sustaining treatment benefits 
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